

Rare and low-frequency coding variants alter human adult height

A full list of authors and affiliations appears at the end of the paper.

Correspondence to:

Joel N. Hirschhorn (joelh@broadinstitute.org)

Panos Deloukas (p.deloukas@qmul.ac.uk)

Guillaume Lettre (guillaume.lettre@umontreal.ca)

Summary: 150 words

Main text: 2,993 words

Three figures and three tables

SUMMARY

Height is a highly heritable, classic polygenic trait with ~700 common associated variants identified so far through genome-wide association studies. Here, we report 83 new height-associated coding variants with lower minor allele frequencies (range of 0.1-4.8%) and effects of up to 2 cm/allele (*e.g.* in *IHH*, *STC2*, *AR* and *CRISPLD2*), >10 times the average effect of common variants. In functional follow-up studies, rare height-increasing variants of *STC2* (+1-2 cm/allele) compromised proteolytic inhibition of PAPP-A and increased cleavage of IGFBP-4 *in vitro*, resulting in higher bioavailability of insulin-like growth factors. These 83 height-associated variants overlap genes mutated in monogenic growth disorders and highlight new biological candidates (*e.g.* *ADAMTS3*, *IL11RA*, *NOX4*) and pathways (*e.g.* proteoglycan/glycosaminoglycan synthesis) involved in growth. Our results demonstrate that sufficiently large sample sizes can uncover rare and low-frequency variants of moderate to large effect associated with polygenic human phenotypes, and that these variants implicate relevant genes and pathways.

INTRODUCTION

Human height is a highly heritable, polygenic trait^{1,2}. The contribution of common DNA sequence variation to inter-individual differences in adult height has been systematically evaluated through genome-wide association studies (GWAS). This approach has thus far identified 697 independent variants located within 423 loci that together explain ~20% of the heritability of height³. As is typical of complex traits and diseases, most of the height alleles discovered so far are common (minor allele frequency (MAF) >5%) and are mainly located outside coding regions, complicating the identification of the relevant genes or functional variants. Identifying coding variants associated with a complex trait in new or known loci has the potential to pinpoint causal genes. Furthermore, the extent to which rare (MAF <1%) and low-frequency (1% < MAF ≤ 5%) coding variants also influence complex traits and diseases remains an open question. Many recent DNA sequencing studies have identified only few such variants⁴⁻⁸, but this limited success could be due to their modest sample size⁹. Some studies have suggested that common sequence variants may explain the majority of the heritable variation in adult height¹⁰, making it timely to assess whether and to what extent rare and low-frequency coding variation contributes to the genetic landscape of this model polygenic trait.

In this study, we used an ExomeChip¹¹ to test the association between 241,453 variants (83% coding with MAF ≤ 5%) and adult height variation in 711,418 individuals (discovery and validation sample sizes are 458,927 and 252,491, respectively). The main goals of our project were to determine whether rare and low-frequency coding variants influence the architecture of a model complex human trait, such as adult height, and to discover and characterize new genes and biological pathways implicated in human growth.

RESULTS

32 rare and 51 low-frequency coding variants associated with adult height

We conducted single-variant meta-analyses in a discovery sample of 458,927 individuals, of whom 381,625 were of European ancestry. We validated our association results in an independent set of 252,491 participants. We first performed standard single-variant association analyses; technical details of the discovery and validation steps are in the **Online Methods (Supplementary Figs 1-6, Supplementary Tables 1-11)**. In total, we found 606 independent ExomeChip variants at array-wide significance ($P < 2 \times 10^{-7}$), including 252 non-synonymous or splice site variants (**Online Methods and Supplementary Table 11**). Focusing on non-synonymous or splice site variants with MAF $< 5\%$, our single-variant analyses identified 32 rare and 51 low-frequency height-associated variants (**Tables 1-2**). To date, these 83 height variants (MAF range 0.1-4.8%) represent the largest set of validated rare and low-frequency coding variants associated with any complex human trait or disease. Among these 83 variants, there are 81 missense, one nonsense (in *CCND3*), and one essential acceptor splice site (in *ARMC5*) variants.

We observed a strong inverse relationship between MAF and effect size that is consistent with our statistical power to discover genetic associations (**Fig. 1**). The largest effect sizes were observed for four rare missense variants, located in the androgen receptor gene *AR* (rs137852591, MAF=0.21%, $P_{\text{combined}}=2.7 \times 10^{-14}$ under recessive model), in *CRISPLD2* (rs148934412, MAF=0.08%, $P_{\text{combined}}=2.4 \times 10^{-20}$), in *IHH* (rs142036701, MAF=0.08%, $P_{\text{combined}}=1.9 \times 10^{-23}$), and in *STC2* (rs148833559, MAF=0.1%, $P_{\text{combined}}=1.2 \times 10^{-30}$). Carriers of the rare *STC2* missense variant are ~2.1 cm taller than non-carriers, whereas carriers of the remaining three variants (or hemizygous men that carry the X-linked *AR*-rs137852591 rare

allele) are ~2 cm shorter than non-carriers. In comparison, the mean effect size of common height alleles is ten times smaller in the same dataset. Across all 83 rare and low-frequency coding variants, the minor alleles were evenly distributed between height-increasing and -decreasing effects (48% vs. 52%, respectively) (**Fig 1.** and **Tables 1-2**).

Coding variants in new and known height loci, and heritability explained

As expected, many of the height-associated variants in this ExomeChip effort are located near common variants previously associated with height. Of the 83 rare and low-frequency coding variants, 49 fell within 1 Mb of a known height signal, but all were found to be independent after conditional analysis using the July 2015 release of the imputed UK Biobank dataset (which contains individual-level genotype data for both ExomeChip and previously associated common height variants); the remaining 34 define new loci. In addition, we found a further 85 common variants and one low-frequency synonymous variant (in *ACHE*) that define novel loci. Thus, our study identified a total of 120 new height loci, plus 49 additional independent signals from rare and low-frequency coding variants at known loci (**Supplementary Table 11**). Because the sample size of the UK Biobank is smaller than our discovery sample size (120,084 vs. 458,927, respectively), we sought to validate the UK Biobank conditional results using an orthogonal imputation-based methodology implemented in the full discovery set (**Online Methods**). As shown in **Supplementary Fig. 7**, both analytical frameworks produced largely compatible results.

We used the UK Biobank dataset to estimate the contribution of the new height variants to heritability, which is $h^2 \sim 80\%$ for adult height². In combination, the 83 rare and low-frequency

variants explained 1.7% of the heritability of height. The newly identified novel common variants accounted for another 2.4%, and all independent variants, known and unknown, together explained 27.4% of heritability. By comparison, the 697 known height SNPs explain 23.3% of height heritability in the same dataset. We observed a modest yet significant positive trend between MAF and heritability explained per variant ($P=0.012$, **Supplementary Fig. 8**), with each common variant explaining slightly more heritability than rare or low-frequency variants (0.029% vs. 0.021%, **Supplementary Fig. 8**).

Gene-based association results

To increase power to find rare or low-frequency coding variants associated with height, we performed gene-based analyses (**Online Methods** and **Supplementary Tables 12-14**). In European-ancestry individuals, the SKAT¹² test (variants with MAF <5% annotated as nonsense, stop-loss, splice site, or damaging missense) identified 99 genes with >1 variant and $P_{SKAT} < 2 \times 10^{-6}$ (**Supplementary Table 13**). These 99 genes are enriched for those involved in syndromes of abnormal skeletal growth (previously identified from the Online Mendelian Inheritance in Man (OMIM) database), located near height SNPs identified by GWAS, or predicted to be causal with bioinformatic tools (**Supplementary Fig. 9**)^{3,13}.

After accounting for gene-based signals explained by a single variant driving the association statistics (**Supplementary Fig. 10**), we identified ten genes that harbor more than one coding variant associated with height variation, and for which the gene-based results remained significant after conditioning on genotypes at nearby common height-associated variants (**Table 3** and **Supplementary Table 15**). Using the same gene-based tests in an independent dataset of 59,804 individuals genotyped on the same exome array, we replicated three genes at $P < 0.05$

(**Table 3**). Further evidence for replication in these genes was seen at the level of single variants (**Supplementary Table 16**). For one of the genes, *OSGIN1*, we found that conditioning on rare variants from this gene affected the results from the single variant analysis. Specifically, two independent variants in *CRISPLD2* (rs149615348, MAF=0.7%, $P=9.1 \times 10^{-12}$; rs2326458, MAF=26%, $P=2.7 \times 10^{-15}$) became less significant after conditioning on *OSGIN1* variants (**Supplementary Fig. 11**). Despite this result, *CRISPLD2* is a promising height candidate gene as a third variant in *CRISPLD2*, the rare missense rs148934412 (MAF=0.08%, $P=7.6 \times 10^{-14}$), remains highly significant after conditioning on *OSGIN1* variants (**Supplementary Fig. 11**). From the gene-based results, three genes – *CSAD*, *NOX4*, and *UGGT2* – fell outside of the loci found by single-variant analyses and are implicated in human height for the first time.

Coding variants implicate biological pathways in human skeletal growth

Prior pathway analyses of height loci identified by GWAS have highlighted gene sets related to both general biological processes (such as chromatin modification and regulation of embryonic size) and more skeletal growth-specific pathways (chondrocyte biology, extracellular matrix (ECM), and skeletal development)³. We used two different methods, DEPICT¹³ and PASCAL¹⁴ (**Online Methods**), to perform pathway analyses using the ExomeChip results to test whether non-synonymous variants could either independently confirm the relevance of these previously highlighted pathways (and further implicate specific genes in these pathways), or identify new pathways. To compare the pathways emerging from coding and non-coding variation, we applied DEPICT separately on (1) exome array-wide significant coding variants independent of known GWAS signals and (2) non-coding GWAS loci, excluding all novel height-associated genes implicated by coding variants. We identified a total of 496 and 1,623 enriched gene sets,

respectively, at a false discovery rate (FDR) <1% (**Supplementary Tables 17-18**); similar analyses with PASCAL yielded 362 and 278 enriched gene sets (**Supplementary Tables 19-20**). Comparison of the results revealed largely shared biology for coding and non-coding variants, especially in the DEPICT analyses, but some pathways showed stronger enrichment with either coding or non-coding variation. In general, coding variants more strongly implicated pathways specific to skeletal growth (such as ECM and bone growth), while GWAS signals highlighted more global biological processes (such as transcription factor binding and embryonic size/lethality)(**Supplementary Fig. 12**). The two gene sets significant in both DEPICT and PASCAL analyses and that were uniquely implicated by coding variants were “BCAN protein protein interaction subnetwork” and “proteoglycan binding.” Both of these pathways relate to the biology of proteoglycans, which are proteins (such as aggrecan) that contain glycosaminoglycans (such as chondroitin sulfate) and that have well-established connections to skeletal growth¹⁵.

We also examined which height-associated genes identified by ExomeChip analyses were driving enrichment of pathways such as proteoglycan binding. Using unsupervised clustering analysis to aid in visualization, we observed that a cluster of height-associated genes is strongly implicated in a group of correlated pathways that include biology related to proteoglycans/glycosaminoglycans (**Fig. 2** and **Supplementary Fig. 13**). Strikingly, many of these genes are already annotated in OMIM as underlying disorders of skeletal growth; as such, the remaining genes may be strong candidates for harboring variants that cause Mendelian growth disorders. Within this group are genes that are largely uncharacterized (*SUSD5*), have relevant biochemical functions (*GLT8D2*, a glycosyltransferase studied mostly in the context of the liver¹⁶; *LOXL4*, a lysyl oxidase expressed in cartilage¹⁷), modulate pathways known to affect

skeletal growth (*FIBIN*, *SFRP4*)^{18,19} or lead to increased body length when knocked out in mice (*SFRP4*)²⁰.

Functional characterization of rare *STC2* variants

To begin exploring whether the identified rare coding variants affect protein function, we performed *in vitro* functional analyses of two rare coding variants in a particularly compelling and novel candidate gene, *STC2*. Over-expression of *STC2* diminishes growth in mice by covalent binding and inhibition of the proteinase PAPP-A, which specifically cleaves IGF binding protein-4 (IGFBP-4), leading to reduced levels of bioactive insulin-like growth factors (**Fig. 3A**)²¹. Although there was no prior genetic evidence implicating *STC2* variation in human growth, the *PAPPA* and *IGFBP4* genes were both implicated in height GWAS³, and rare mutations in *PAPPA2* cause severe short stature²², emphasizing the likely relevance of this pathway in humans. The two *STC2* height-associated variants are rs148833559 (p.Arg44Leu, MAF=0.096%, $P_{\text{discovery}}=5.7 \times 10^{-15}$) and rs146441603 (p.Met86Ile, MAF=0.14%, $P_{\text{discovery}}=2.1 \times 10^{-5}$). These rare alleles increase height by 1.9 and 0.9 cm, respectively, suggesting that they both partially impair *STC2* function. In functional studies, *STC2* with these amino acid substitutions were expressed at similar levels to wild-type, but showed clear, partial defects in binding to PAPP-A and in inhibition of PAPP-A-mediated cleavage of IGFBP-4 (**Fig. 3B-D**). Thus, the genetic analysis successfully identified rare coding alleles that have demonstrable and predicted functional consequences, strongly confirming the role of these variants and the *STC2* gene in human growth.

Pleiotropic effects and clinical significance

Previous GWAS studies have reported pleiotropic or secondary effects on other phenotypes for many common variants associated with adult height^{3,23}. Therefore, we explored to which extent the identified coding variants are associated with 17 human complex phenotypes for which well-powered meta-analysis results were available. Of the 606 height variants identified by single-variant analyses in this study, we found that 96 were associated with at least one of the other investigated traits at array-wide significance ($P < 2 \times 10^{-7}$), including one rare and five low-frequency missense variants (see below, **Supplementary Fig. 14**, and **Supplementary Table 21**). Overall, the 606 height signals were enriched for variants nominally associated with body mass index (BMI; $P_{\text{binomial}} = 1.2 \times 10^{-10}$), LDL-cholesterol (LDL-C; $P_{\text{binomial}} = 3.5 \times 10^{-6}$), total cholesterol (TC; $P_{\text{binomial}} = 4.4 \times 10^{-8}$), triglycerides (TG; $P_{\text{binomial}} = 8.9 \times 10^{-7}$) and coronary artery disease (CAD; $P_{\text{binomial}} = 6.0 \times 10^{-10}$) (**Supplementary Table 22**).

Of the rare and low-frequency missense variants associated with other traits at array-wide significance, the minor alleles at rs77542162 (*ABCA6*, MAF=1.7%) and rs28929474 (*SERPINA1*, MAF=1.8%) were associated with increased height and increased levels of LDL-C and TC, whereas the minor allele at rs3208856 in *CBLC* (MAF=3.4%) was associated with increased height, HDL-cholesterol (HDL-C) and TG, but lower LDL-C and TC levels. The minor allele at rs141845046 (*ZBTB7B*, MAF=2.8%) was associated with both increased height and BMI. The minor alleles at the other two missense variants associated with shorter stature, rs201226914 in *PIEZO1* (MAF=0.2%) and rs35658696 in *PAM* (MAF=4.8%), were associated with decreased glycated haemoglobin (HbA1c) and increased type 2 diabetes risk, respectively. Consistent with a recent report²⁴, the most pleiotropic variant that we found was the missense rs13107325 (MAF=6.2%) in *SLC39A8*: the minor allele is associated with decreased height,

increased BMI, decreased HDL-C, LDL-C, and TC, but increased TG, and decreased systolic and diastolic blood pressure (**Supplementary Fig. 14** and **Supplementary Table 21**). Rare mutations in *SLC39A8* cause variable short stature phenotypes^{25,26}, whereas common variants in this gene were previously associated with metabolic syndrome, inflammation, and hypertension²⁷⁻³⁰.

Our set of variants associated with height includes several missense variants in genes underlying monogenic syndromes affecting skeletal growth such as *ACAN* (MIM 165800, 608361), *PTH1R* (MIM 60002, 215045), *IHH* (MIM 607778, 112500), *FBN2* (MIM 121050), *ADAMTS10* (MIM 277600) and *ADAMTS17* (MIM 613195) (**Supplementary Table 11**). To further explore the clinical significance of height variants, we queried the ClinVar database and retrieved information on 8,736 variants, including 1,446 markers that are, or predicted to be, pathogenic (**Supplementary Fig. 15** and **Supplementary Table 23**). Of this group, The NIH Genetic Testing Registry recommends testing for four height-associated variants. Two coding variants (rs80356487, MAF=0.03%, β =-1.7 cm; rs1801175, MAF=0.04%, β =-1.2 cm) are located in *G6PC*. Mutations in *G6PC* cause glycogen storage disorder type Ia (von Gierke Disease), which is characterized by growth retardation, delayed puberty, and metabolic abnormalities (MIM 232200). The other two variants are rs1800562 (MAF=6.0%, β =+0.2 cm) in *HFE*, which causes type-1 hemochromatosis (MIM 235200), and rs28929474 (MAF=1.8%, β =+0.8 cm) in the α -1-antitrypsin gene *SERPINA1* (**Supplementary Table 23**). When homozygous, the *SERPINA1*-rs28929474 variant is a cause of emphysema and liver disease in European-descent individuals, and an important risk factor for severe liver disease in cystic fibrosis patients³¹. This is intriguing given that the low-frequency *SERPINA1* allele at rs28929474 is associated with increased height and milder complication in patients with cystic fibrosis due to improve lung functions³².

DISCUSSION

We undertook an association study of nearly 200,000 non-synonymous variants in 711,418 individuals, and identified 32 rare and 51 low-frequency coding variants associated with adult height. Furthermore, gene-based testing discovered 10 genes that harbor several additional rare/low-frequency variants associated with height, including three genes (*CSAD*, *NOX4*, *UGGT2*) in loci not previously implicated in height. In total, our results highlight 89 genes (10 from gene-based testing and 79 from single-variant analyses (four genes have 2 independent coding variants)) that are likely to modulate human growth, and 24 alleles segregating in the general population that affect height by more than 1 cm (**Tables 1-3**). The rare and low-frequency coding variants explain 1.7% of the heritable variation in adult height. When considering all rare, low-frequency, and common height-associated variants validated in this study, we can now explain 27.4% of the heritability. On a per variant basis, we found that common height SNPs explain more heritability than rare or low-frequency variants (0.029% vs. 0.021%). This suggests that the effect size of rare/low-frequency variants, despite being larger than for common SNPs (**Fig. 1**), is not as large as initially anticipated. Overall, our findings provide strong evidence that rare and low-frequency coding variants contribute to the genetic architecture of height, a model complex human trait.

Our analyses revealed many coding variants in genes mutated in monogenic skeletal growth disorders (**Supplementary Fig. 9**), confirming the presence of allelic series (from familial penetrant mutations to mild effect common variants) in the same genes for related growth phenotypes in humans. We used gene set enrichment-type analyses to demonstrate the functional connectivity between the genes that harbor coding height variants, highlighting known as well as novel biological pathways that regulate height in humans (**Fig. 2, Supplementary Fig. 13** and

Supplementary Tables 17-20), and newly implicating genes such as *SUSD5*, *GLT8D2*, *LOXL4*, *FIBIN*, and *SFRP4* that have not been previously connected with skeletal growth. Additional interesting height candidate genes include *NOX4*, *ADAMTS3* and *ADAMTS6*, *PTH1R*, and *IL11RA* (**Tables 1-2, Supplementary Tables 15 and 24**). *NOX4*, identified through gene-based testing, encodes NADPH oxidase 4, an enzyme that produces reactive oxygen species, a biological pathway not previously implicated in human growth. *Nox4*^{-/-} mice display higher bone density and reduced numbers of osteoclasts, a cell type essential for bone repair, maintenance, and remodelling¹². We also found rare coding variants in *ADAMTS3* and *ADAMTS6*, genes that encode metalloproteinases that belong to the same family than several other human growth syndromic genes (e.g. *ADAMTS2*, *ADAMTS10*, *ADAMTSL2*). Moreover, we discovered a rare missense variant in *PTH1R* that encodes a receptor of the parathyroid hormone (PTH): PTH-PTH1R signaling is important for bone resorption and mutations in *PTH1R* cause chondrodysplasia in humans³³. Finally, we replicated the association between a low-frequency missense variant in the cytokine gene *IL11*, but also found a new low-frequency missense variant in its receptor gene *IL11RA*. The IL11-IL11RA axis has been shown to play an important role in bone formation in the mouse^{34,35}. Thus, our data confirm the relevance of this signaling cascade in human growth as well. Taken together, the identification of specific genes implicated in human height variation has the potential: (1) to elucidate biological mechanisms that control growth, (2) to provide candidate genes for orphan syndromes characterized by abnormal height phenotypes, and (3) to guide the development of new therapeutic strategies for growth defects. In that regard, the identification of rare missense height-increasing variants of large effect size in *STC2*, and the functional characterization of their effect on IGF signaling, is particularly promising.

286 **ACKNOWLEDGMENTS**

287 A full list of acknowledgments appears in the **Supplementary Note**. Part of this work was
288 conducted using the UK Biobank resource.

289

290

291 **AUTHOR CONTRIBUTIONS**

292 *Writing Group (wrote and edited manuscript)*

293 Panos Deloukas, Timothy M. Frayling, Mariaelisa Graff, Joel N. Hirschhorn, Guillaume Lettre,
294 Ken Sin Lo, Yingchang Lu, Eirini Marouli, M. Carolina Medina-Gomez, Fernando Rivadeneira.
295

296 *Data preparation group (checked and prepared data from contributing cohorts for meta-*
297 *analyses and replication)*

298 Tonu Esko, Mariaelisa Graff, Heather Highland, Anne Justice, Tugce Karaderi, Ken Sin Lo,
299 Adam E. Locke, Yingchang Lu, Eirini Marouli, Nicholas G.D. Masca, M. Carolina Medina-
300 Gomez, Poorva Mudgal, Maggie C.Y. Ng, Manuel A. Rivas, Claudia Schurmann, Kathy
301 Stirrups, Valérie Turcot, Sailaja Vedantam, Thomas W. Winkler, Kristin L. Young.

302

303 *Height meta-analyses (discovery and replication, single-variant and gene-based)*

304 Panos Deloukas, Timothy M. Frayling, Mariaelisa Graff, Joel N. Hirschhorn, Guillaume Lettre,
305 Daijiang J. Liu, Ken Sin Lo, Yingchang Lu, Eirini Marouli, M. Carolina Medina-Gomez,
306 Fernando Rivadeneira, Andrew R. Wood.

307

308 *UK Biobank-based integration of height association signals group and heritability analyses*

309 Panos Deloukas, Timothy M. Frayling, Guillaume Lettre, Zoltán Kutalik, Ken Sin Lo, Eirini
310 Marouli, Sina Rüeger, Andrew R. Wood.

311

312 *Pleiotropy working group*

313 Gonçalo Abecasis, Michael Boehnke, James P. Cook, Panos Deloukas, Fotios Drenos, Jose C.

314 Florez, Heather Highland, Sekar Kathiresan, Cecilia M. Lindgren, Dajiang J. Liu, Ruth J.F.
315 Loos, Anubha Mahajan, Eirini Marouli, Mark I. McCarthy, Patricia B. Munroe, Gina M. Peloso,
316 John R. B. Perry, Katherine S. Ruth, Cristen J. Willer.
317
318 *Biological and clinical enrichment, and pathway analyses*
319 Rebecca S. Fine, Joel N. Hirschhorn, Zoltán Kutalik, David Lamparter, Guillaume Lettre, Ken
320 Sin Lo, Tune H. Pers.
321
322 *Functional characterization of STC2*
323 Troels R. Kjaer, Claus Oxvig.
324

ONLINE METHODS

Study design & participants

The discovery cohort consisted of 147 studies comprising 458,927 adult individuals of the following ancestries: 1) European descent (N=381,625), 2) African (N=27,494), 3) South Asian (N=29,591), 4) East Asian (N=8,767); 5) Hispanic (N=10,776) and 6) Saudi (N=695). Discovery meta-analysis was carried out in each ancestry group (except the Saudi) separately as well as in the All group. Replication was undertaken in individuals of European ancestry only (**Supplementary Tables 1-3**). Conditional analyses were undertaken only in the European descent group (106 studies, N=381,625).

Phenotype

Height (in centimeters) was corrected for age and the genomic principal components (derived from GWAS data, the variants with MAF >1% on ExomeChip, or ancestry informative markers available on the ExomeChip), as well as any additional study-specific covariates (e.g. recruiting center), in a linear regression model. For studies with non-related individuals, residuals were calculated separately by sex, whereas for family-based studies sex was included as a covariate in the model. Additionally, residuals for case/control studies were calculated separately. Finally, residuals were subject to inverse normal transformation.

Genotype calling

The majority of studies followed a standardized protocol and performed genotype calling using the designated manufacturer software, which was then followed by zCall³⁶. For 10 studies participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology

(CHARGE) Consortium, the raw intensity data for the samples from seven genotyping centers were assembled into a single project for joint calling¹¹. Study-specific quality control (QC) measures of the genotyped variants was implemented before association analysis (Supplementary Tables 1-2).

Study-level statistical analyses

Individual cohorts were analyzed separately for each ancestry population, with either RAREMETALWORKER (<http://genome.sph.umich.edu/wiki/RAREMETALWORKER>) or RVTEST (<http://zhanxw.github.io/rvtests/>), to associate inverse normal transformed height data with genotype data taking potential cryptic relatedness (kinship matrix) into account in a linear mixed model. These software are designed to perform score-statistics based rare-variant association analysis, can accommodate both unrelated and related individuals, and provide single-variant results and variance-covariance matrix. The covariance matrix captures linkage disequilibrium (LD) relationships between markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses³⁷. Single-variant analyses were performed for both additive and recessive models.

Centralized quality-control

The individual study data were investigated for potential existence of ancestry population outliers based on 1000 Genome Project phase 1 ancestry reference populations. A centralized QC procedure implemented in EasyQC³⁸ was applied to individual study association summary statistics to identify outlying studies: (1) assessment of possible problems in height transformation, (2) comparison of allele frequency alignment against 1000 Genomes Project

phase 1 reference data to pinpoint any potential strand issues, and (3) examination of quantile-quantile (QQ) plots per study to identify any problems arising from population stratification, cryptic relatedness and genotype biases.

Meta-analyses

Meta-analyses were carried out in parallel by two different analysts at two sites. We excluded variants if they had call rate <95%, Hardy-Weinberg equilibrium $P < 1 \times 10^{-7}$, or large allele frequency deviations from reference populations (>0.6 for all ancestry analyses and >0.3 for ancestry-specific population analyses). We also excluded from downstream analyses markers not present on the Illumina ExomeChip array 1.0, variants on the Y-chromosome or the mitochondrial genome, indels, multiallelic variants, and problematic variants based on the Blat-based sequence alignment analyses. Significance for single-variant analyses was defined at array-wide level ($P < 2 \times 10^{-7}$, Bonferroni correction for 250,000 variants). For the gene-based analyses, we applied two different sets of criteria to select variants, based on coding variant annotation from five prediction algorithms (PolyPhen2 HumDiv and HumVar, LRT, MutationTaster and SIFT)³⁹. The mask labeled “*broad*” included variants with a MAF <0.05 that are nonsense, stop-loss, splice site, as well as missense variants that are annotated as damaging by at least one program mentioned above. The mask labeled “*strict*” included only variants with MAF <0.05 that are nonsense, stop-loss, splice site, as well as missense variants annotated as damaging by all five algorithms. We used two tests for gene-based testing, namely the SKAT¹² and VT⁴⁰ tests. Statistical significance for gene-based tests was set at a Bonferroni-corrected threshold of $P < 2 \times 10^{-6}$ (threshold for 25,000 genes; we did not correct for the four tests given that they are correlated and that we sought validation in independent studies).

Genomic inflation

We observed a marked genomic inflation of the test statistics even after adequate control for population stratification (linear mixed model) arising mainly from common markers; λ_{GC} in European-ancestry was 1.2 and 2.7 for all and common markers, respectively (**Supplementary Fig. 2** and **Supplementary Table 8**). Such inflation is expected for a highly polygenic trait like height, and is consistent with our very large sample size^{3,41}. To confirm this, we applied the recently developed linkage disequilibrium (LD) score regression method to our height ExomeChip results⁴², with the caveats that the method was developed (and tested) with >200,000 common markers available. We restricted our analyses to 15,848 common variants (MAF $\geq 5\%$) from the European-ancestry meta-analysis, and matched them to pre-computed LD scores for the European reference dataset⁴². The intercept of the regression of the χ^2 statistics from the height meta-analysis on the LD score estimate the inflation in the mean χ^2 due to confounding bias, such as cryptic relatedness or population stratification. The intercept is 1.4 (standard error = 0.07), which is small when compared to the λ_{GC} of 2.7. The ratio statistic of (intercept -1) / (mean χ^2 -1) is 0.067 (standard error = 0.012), well within the normal range⁴², suggesting that most of the inflation (~93%) observed in the height association statistics is due to polygenic effects (**Supplementary Fig. 3**).

Furthermore, to exclude the possibility that some of the observed associations between height and rare/low-frequency variants could be due to allele calling problems in the smaller studies, we performed a sensitivity meta-analysis with primarily Europe-ancestry studies totaling >5,000

participants. We found very concordant effect sizes, suggesting that smaller studies do not bias our results (**Supplementary Fig. 4**).

Conditional analyses

The RAREMETAL R-package⁴³ and the GCTA v1.24⁴⁴ software were used to identify independent height association signals across the European descent meta-analysis results. RAREMETAL performs conditional analyses by using covariance matrices in order to distinguish true signals from those driven by LD with adjacent known variants. First, we identified the lead variants ($P < 2 \times 10^{-7}$) based on a 1 Mb window centered on the most significantly associated variant and performed LD pruning ($r^2 < 0.3$) to avoid downstream problems in the conditional analyses due to co-linearity. We then conditioned on the LD-pruned set of lead variants in RAREMETAL and kept new lead signals at $P < 2 \times 10^{-7}$. The process was repeated until no additional signal emerged below the pre-specified P-value threshold. The use of a 1Mb window in RAREMETAL can obscure dependence between conditional signals in adjacent intervals in regions of extended LD. To detect such instances, we performed joint analyses using GCTA in the ARIC and UK ExomeChip reference panels, both of which comprise >10,000 individuals of European descent. Gene-based conditional analyses were also performed in RAREMETAL.

The newly discovered 120 height variants were conditioned on the previously published GWAS height variants³ in the first release of the UK Biobank imputed dataset using regression methodology implemented in BOLT-LMM⁴⁵. We also explored an alternative approach based on approximate conditional analysis⁴⁴. This latter method relies on summary statistics available

from the same cohort, thus we first imputed summary statistics⁴⁶ for exome variants, using summary statistics from the Wood et al. 2014 study³. Conversely, we imputed the top variants from the Wood et al. 2014 study using the summary statistics from the ExomeChip. Subsequently, we calculated effect sizes for each exome variant conditioned on the Wood et al. 2014 top variants in two ways. First, we conditioned the imputed summary statistics of the exome variant on the summary statistics of the Wood et al. 2014 top variants that fell within 5 Mb of the target ExomeChip variant. Second, we conditioned the summary statistics of the ExomeChip variant on the imputed summary statistics of the Wood et al. 2014 hits. We then selected the option that yielded a higher imputation quality. For poorly tagged variants ($\hat{r}^2 < 0.8$), we simply used up-sampled HapMap summary statistics for the approximate conditional analysis. Pairwise SNP-by-SNP correlations were estimated from the UK10K data (TwinsUK⁴⁷ and ALSPAC⁴⁸ studies, N=3,781).

Description of the single-variant analyses

We conducted single-variant meta-analyses in a discovery sample of 458,927 individuals of different ancestries using both additive and recessive genetic models (**Supplementary Fig. 1** and **Supplementary Tables 1-4**). The combined additive analyses identified 1,455 unique variants that reached array-wide significance ($P < 2 \times 10^{-7}$), including 578 non-synonymous and splice site variants (**Supplementary Tables 5-7**). Under the additive model, we observed a high genomic inflation of the test statistics (e.g. λ_{GC} of 2.7 in European-ancestry studies for common markers, **Supplementary Fig. 2** and **Supplementary Table 8**), although replication results (see below) and additional sensitivity analyses (see above) suggest that it is consistent with polygenic inheritance as opposed to population stratification, cryptic relatedness, or technical artifacts

(**Supplementary Figs 3-4**). The majority of these 1,455 association signals (1,241; 85.3%) were found in the European-ancestry meta-analysis (85.5% of the discovery sample size) (**Supplementary Fig. 5**). Nevertheless, we discovered eight associations within five loci in our all-ancestry analyses that are driven by African studies (including one missense variant in the growth hormone gene *GHI* (rs151263636), **Supplementary Fig. 6**), three height variants found only in African studies, and one rare missense marker associated with height in South Asians only (**Supplementary Table 7**).

Several studies, totaling 252,491 independent individuals of European ancestry, became available after the completion of the discovery analyses, and were thus used for validation of our experiment. First, we considered the 81 variants with suggestive association in the discovery analyses ($2 \times 10^{-7} < P_{\text{discovery}} \leq 2 \times 10^{-6}$). Of those 81 variants, 55 reached significance after combining discovery and replication results based on $P_{\text{combined}} < 2 \times 10^{-7}$ (**Supplementary Table 9**).

Furthermore, recessive modeling confirmed seven new independent markers with $P_{\text{combined}} < 2 \times 10^{-7}$, including one rare missense variant (rs137852591, MAF 0.21%) in the *AR* gene (**Supplementary Table 10**). To test the independence and integrate all height markers from the discovery and replication phase, we used conditional analyses and GCTA “joint” modeling⁴⁴ in the combined discovery and replication set. This resulted in the identification of 606 independent height variants, including 252 non-synonymous or splice site variants (**Supplementary Table 11**). Of the 606 variants, 605 had concordant direction of effect between the discovery and validation studies, and 595 variants had a $P_{\text{validation}} < 0.05$ (482 variants with $P_{\text{validation}} < 8 \times 10^{-5}$, Bonferroni correction for 606 tests), suggesting a very low false discovery rate (**Supplementary Table 11**).

Pathway analyses

DEPICT is a computational framework that uses probabilistically-defined reconstituted gene sets to perform gene set enrichment and gene prioritization¹³. For a description about gene set reconstitution please refer to references¹³ and⁴⁹. In brief, reconstitution was performed by extending pre-defined gene sets (such as Gene Ontology terms, canonical pathways, protein-protein interaction subnetworks and rodent phenotypes) with genes co-regulated with genes in these pre-defined gene set using large-scale microarray-based transcriptomics data. In order to adapt the gene set enrichment part of DEPICT for ExomeChip data, we made two principal changes. First and foremost, because DEPICT for GWAS incorporates all genes within a given LD block around each index SNP, we modified DEPICT to take as input only the gene directly impacted by the coding SNP. Second, we adapted the way DEPICT adjust for confounders (such as gene length) by generating null ExomeChip association results using Swedish ExomeChip data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS), and Scania Diabetes Registry (SDR) cohorts, N=11,899) and randomly assigning phenotypes from a normal distribution before conducting association analysis (see **Supplementary Note**). For the gene set enrichment analysis of the ExomeChip data, we used significant non-synonymous variants statistically independent of known GWAS hits (and that were present in the null ExomeChip data; See Supplementary Note for details). For gene set enrichment analysis of the GWAS data, we used all loci (1) with a non-coding index SNP and (2) that did not contain any of the novel ExomeChip genes. In visualizing the analysis, we used affinity propagation clustering⁵⁰ to group the most similar reconstituted gene sets based on their gene memberships (See Supplementary Note). Within a “meta-gene set”, the best P-value of any member gene set was used as

representative for comparison. DEPICT for ExomeChip was written using the Python programming language and the code can be found at <https://github.com/perslab/ec-depict>. We also applied the PASCAL pathway analysis tool¹⁴ to genome-wide association summary statistics for all coding variants. In brief, the method derives gene-based scores (both SUM and MAX statistics) and subsequently tests for the over-representation of high gene scores in predefined biological pathways. We used standard pathway libraries from KEGG, REACTOME and BIOCARTEA, and also added dichotomized (Z-score>3) reconstituted gene sets from DEPICT¹³. To accurately estimate SNP-by-SNP correlations even for rare variants, we used the UK10K data (TwinsUK⁴⁷ and ALSPAC⁴⁸ studies, N=3781). In order to separate the contribution of regulatory variants from the coding variants, we also applied PASCAL to association summary statistics of only regulatory variants (20 kb upstream, gene body excluded) from the Wood et al. study³. In this way, we could classify pathways driven principally by coding, regulatory or mixed signals.

Validation

We performed single-variant and gene-based association analyses for eight validation studies, totaling 59,804 participants, genotyped on the Exomechip using RAREMETAL³⁷. We sought additional evidence for association for the top signals in two independent studies in the UK (UK Biobank) and Iceland (deCODE), comprising 120,084 and 72,613 individuals, respectively. We used the same QC and analytical methodology as described above. Genotyping and study descriptives are provided in **Supplementary Tables 1-3**. For the combined analysis, we used the inverse-variance weighted fixed effects meta-analysis method using METAL⁵¹. Significant

associations were defined as those with a combined meta-analysis (discovery and validation)

$P_{\text{combined}} < 2 \times 10^{-7}$.

STC2 functional experiments

Mutagenesis, cell culture and transfection. For the generation of STC2 mutants (R44L and M86I), wild-type STC2 cDNA contained in pcDNA3.1/Myc-His(-) (Invitrogen)²¹ was used as a template. Mutagenesis was carried out using Quickchange (Stratagene), and all constructs were verified by sequence analysis. Recombinant wild-type STC2 and variants were expressed in human embryonic kidney (HEK) 293T cells (293tsA1609neo) maintained in high-glucose DMEM supplemented 10% fetal bovine serum, 2 mM glutamine, nonessential amino acids, and gentamicin. Cells (6×10^6) were plated onto 10 cm-dishes and transfected 18 h later by calcium phosphate coprecipitation using 10 µg plasmid DNA. Media were harvested 48 h post transfection, cleared by centrifugation, and stored at -20°C until use. Protein concentrations (58-66 nM) were determined by TRIFMA using antibodies described previously²¹. PAPP-A was expressed stably in HEK293T cells as previously reported⁵². Expressed levels of PAPP-A (27.5 nM) were determined by a commercial ELISA (AL-101, Ansh Labs, TX).

STC2 and PAPP-A complex formation. Culture supernatants containing wild-type STC2 or variants were adjusted to 58 nM, added an equal volume of culture supernatant containing PAPP-A corresponding to a 2.1-fold molar excess, and incubated at 37°C. Samples were taken at 1, 2, 4, 6, 8, 16, and 24 h and stored at -20°C.

Analysis of proteolytic activity. Specific proteolytic cleavage of ¹²⁵I-labeled IGFBP-4 is described in detail elsewhere⁵³. Briefly, the PAPP-A:STC2 complex mixtures were diluted (1:190) to a concentration of 145 pM PAPP-A and mixed with preincubated ¹²⁵I-IGFBP4 (10 nM) and IGF-1 (100 nM) in 50 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl₂. Following 1 h incubation at 37°C, reactions were terminated by the addition of SDS-PAGE sample buffer supplemented with 25 mM EDTA. Substrate and co-migrating cleavage products were separated by 12% nonreducing SDS-PAGE and visualized by autoradiography using a storage phosphor screen (GE Healthcare) and a Typhoon imaging system (GE Healthcare). Band intensities were quantified using ImageQuant TL 8.1 software (GE Healthcare).

Western blotting. STC2 and covalent complexes between STC2 and PAPP-A were blotted onto PVDF membranes (Millipore) following separation by 3-8% SDS-PAGE. The membranes were blocked with 2% Tween-20, and equilibrated in 50 mM Tris-HCl, 500 mM NaCl, 0.1% Tween-20, pH 9 (TST). For STC2, the membranes were incubated with goat polyclonal anti-STC2 (R&D systems, AF2830) at 0.5 µg/ml in TST supplemented with 2% skim milk for 1 h at 20°C. For PAPP-A:STC2 complexes, the membranes were incubated with rabbit polyclonal anti-PAPP-A⁵⁴ at 0.63 µg/ml in TST supplemented with 2% skim milk for 16 h at 20°C. Membranes were washed with TST and subsequently incubated with polyclonal swine anti-rabbit IgG-HRP (DAKO, P0217) or polyclonal rabbit anti-goat IgG-HRP (DAKO, P0449), respectively, diluted 1:2000 in TST supplemented with 2% skim milk for 1 h at 20°C. Following washing with TST, membranes were developed using enhanced chemiluminescence (ECL Prime, GE Healthcare). Images were captured using an ImageQuant LAS 4000 instrument (GE Healthcare).

576 *Pleiotropy analyses*

577 We accessed ExomeChip data from GIANT (BMI, waist-hip ratio), GLGC (total cholesterol
578 (TC), triglycerides (TG), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C)), IBPC (systolic
579 and diastolic blood pressure), MAGIC (glycaemic traits), REPROGEN (age at menarche and
580 menopause), and DIAGRAM (type 2 diabetes). For coronary artery disease, we accessed 1000
581 Genomes Project-imputed GWAS data released by CARDIoGRAMplusC4D⁵⁵.

582

583 **URLs**

584 ClinVar, <http://www.ncbi.nlm.nih.gov/clinvar/>

585 DEPICT, <http://www.broadinstitute.org/mpg/depict/>

586 ExomeChip, http://genome.sph.umich.edu/wiki/Exome_Chip_Design

587 ExomeDEPICT, <https://github.com/perslab/ec-depict>

588 OMIM, <http://omim.org/>

589 PASCAL, <http://www2.unil.ch/cbg/index.php?title=Pascal>

590 RAREMETALWORKER, <http://genome.sph.umich.edu/wiki/RAREMETALWORKER>

591 RVTEST, <http://zhanxw.github.io/rvtests/>

592 **Table 1. Rare variants associated with adult height.** 32 coding or splice site variants with minor allele frequency <1% in European-ancestry
593 participants that have $P_{\text{combined}} < 2 \times 10^{-7}$. All markers are significant under an additive genetic model, except AR-rs137852591, which was discovered
594 using the recessive model in the all-ancestry analysis. The direction of the effect (Beta) and effect allele frequency (AF) is given for the alternate
595 (Alt) allele. Genomic coordinates are on build 37 of the human genome. For each variant, we provide the most severe annotation using the
596 ENSEMBL Variant Effect Predictor (VEP) tool. N, sample size; Ref, reference allele; SE, standard error.

Variant	Chr:Pos	Ref/Alt	Gene	Annotation	Discovery (N up to 381,625)				Validation (N up to 252,491)				Combined (N up to 634,116)			
					AF	Beta	SE	P-value	AF	Beta	SE	P-value	AF	Beta	SE	P-value
rs150341307	1:32673514	G/C	<i>IQCC</i>	missense	0.002	-0.141	0.026	7.92E-08	0.004	-0.116	0.025	3.83E-06	0.003	-0.128	0.018	1.34E-12
rs143365597	1:41540902	G/A	<i>SCMH1</i>	missense	0.004	0.188	0.018	1.58E-25	0.006	0.169	0.024	9.42E-13	0.005	0.181	0.014	1.35E-36
rs114233776	1:41618297	G/A	<i>SCMH1</i>	missense	0.006	-0.119	0.015	1.92E-15	0.006	-0.11	0.019	1.32E-08	0.006	-0.116	0.012	1.80E-22
rs145659444	1:149902342	C/T	<i>MTMR11</i>	missense	0.007	0.067	0.015	4.16E-06	0.006	0.083	0.019	7.11E-06	0.007	0.073	0.012	3.03E-10
rs144712473	1:183495812	A/G	<i>SMG7</i>	missense	0.006	-0.094	0.014	4.97E-11	0.008	-0.067	0.017	8.94E-05	0.007	-0.083	0.011	1.61E-14
rs144673025	1:223178026	T/C	<i>DISP1</i>	missense	0.008	-0.078	0.013	1.11E-09	0.007	-0.086	0.018	1.22E-06	0.008	-0.081	0.011	1.27E-14
rs142036701	2:219924961	G/T	<i>IHH</i>	missense	0.001	-0.32	0.04	1.09E-15	0.003	-0.263	0.043	1.48E-09	0.002	-0.294	0.029	1.85E-23
rs147445258	2:220078652	C/T	<i>ABCB6</i>	missense	0.01	-0.086	0.012	3.43E-13	0.009	-0.064	0.018	4.40E-04	0.01	-0.079	0.01	2.47E-15
rs121434601	3:46939587	C/T	<i>PTH1R</i>	missense	0.003	0.154	0.023	1.30E-11	0.003	0.192	0.031	5.48E-10	0.003	0.168	0.019	1.14E-19
rs141374503	4:73179445	C/T	<i>ADAMTS3</i>	missense	0.003	-0.119	0.021	1.82E-08	0.004	-0.089	0.023	1.32E-04	0.004	-0.106	0.016	1.30E-11
rs149385790	4:120422407	T/G	<i>PDE5A</i>	missense	0.001	0.257	0.031	7.50E-17	0.005	0.19	0.033	1.28E-08	0.003	0.226	0.023	2.65E-23
rs146301345	5:32784907	G/A	<i>NPR3</i>	missense	0.003	0.128	0.022	1.05E-08	0.002	0.166	0.035	1.78E-06	0.003	0.139	0.019	7.91E-14
rs61736454	5:64766798	G/A	<i>ADAMTS6</i>	missense	0.002	-0.152	0.026	7.82E-09	0.002	-0.182	0.032	1.37E-08	0.002	-0.164	0.02	4.80E-16
rs78727187	5:127668685	G/T	<i>FBN2</i>	missense	0.006	0.183	0.015	2.47E-33	0.006	0.181	0.02	5.06E-20	0.006	0.182	0.012	1.47E-52
rs148833559	5:172755066	C/A	<i>STC2</i>	missense	0.001	0.29	0.037	5.69E-15	0.001	0.368	0.043	1.32E-17	0.001	0.323	0.028	1.15E-30
rs148543891	6:155450779	A/G	<i>TIAM2</i>	missense	0.003	-0.124	0.022	1.45E-08	0.001	-0.016	0.082	8.50E-01	0.003	-0.117	0.021	3.96E-08
rs41511151	7:73482987	G/A	<i>ELN</i>	missense	0.004	-0.086	0.018	2.63E-06	0.007	-0.061	0.019	1.51E-03	0.006	-0.074	0.013	2.31E-08
rs112892337	8:135614553	G/C	<i>ZFAT</i>	missense	0.004	0.196	0.019	4.42E-26	0.004	0.184	0.024	1.20E-14	0.004	0.191	0.015	6.12E-38
rs75596750	8:135622851	G/A	<i>ZFAT</i>	missense	0.001	0.255	0.036	1.54E-12	0.002	0.339	0.039	5.94E-18	0.002	0.293	0.027	2.05E-28
rs138273386	11:27016360	G/A	<i>FIBIN</i>	missense	0.004	-0.12	0.017	5.79E-12	0.005	-0.076	0.024	1.56E-03	0.004	-0.105	0.014	3.26E-14
rs138059525	11:94533444	G/A	<i>AMOTL1</i>	missense	0.009	-0.096	0.012	9.01E-16	0.007	-0.089	0.017	3.84E-07	0.008	-0.094	0.01	2.84E-21
rs147996581	12:58138971	G/A	<i>TSPAN31</i>	missense	0.003	-0.116	0.022	8.26E-08	0.001	-0.268	0.09	2.85E-03	0.003	-0.125	0.021	5.50E-09
rs13141	12:121756084	G/A	<i>ANAPC5</i>	missense	0.009	-0.082	0.012	1.09E-11	0.011	-0.105	0.016	1.44E-11	0.01	-0.091	0.01	1.45E-21
rs150494621	15:44153571	C/T	<i>WDR76</i>	missense	0.008	0.063	0.013	1.56E-06	0.014	0.054	0.015	3.42E-04	0.011	0.059	0.01	2.32E-09
rs141308595	15:89424870	G/T	<i>HAPLN3</i>	missense	0.001	-0.267	0.037	2.84E-13	0.002	-0.234	0.035	2.43E-11	0.002	-0.25	0.025	1.02E-22
rs141923065	16:31474091	A/G	<i>ARMC5</i>	splice acceptor	0.006	0.104	0.015	5.88E-12	0.013	0.057	0.018	1.16E-03	0.009	0.084	0.011	1.62E-13
rs34667348	16:47684830	C/A	<i>PHKB</i>	missense	0.005	0.121	0.016	3.96E-14	0.005	0.033	0.020	1.04E-01	0.005	0.088	0.013	3.43E-12
rs140385822	16:67470505	G/A	<i>HSD11B2</i>	missense	0.002	-0.148	0.028	1.27E-07	0.002	-0.124	0.035	3.38E-04	0.002	-0.139	0.022	1.97E-10
rs149615348	16:84900645	G/A	<i>CRISPLD2</i>	missense	0.007	-0.095	0.014	9.13E-12	0.008	-0.098	0.017	4.34E-09	0.008	-0.096	0.011	2.92E-19
rs148934412	16:84902472	G/A	<i>CRISPLD2</i>	missense	0.001	-0.297	0.04	7.75E-14	0.001	-0.317	0.058	3.49E-08	0.001	-0.304	0.033	2.36E-20
rs201226914	16:88798919	G/T	<i>PIEZO1</i>	missense	0.002	-0.187	0.027	5.27E-12	0.002	-0.241	0.043	1.99E-08	0.002	-0.202	0.023	8.68E-19
rs137852591	23:66941751	C/G	<i>AR</i>	missense	0.002	-0.304	0.061	7.05E-07	0.008	-0.333	0.058	7.12E-09	0.005	-0.319	0.042	2.67E-14

598 **Table 2. Low-frequency variants associated with adult height.** 59 variants (51 coding) with minor allele frequency between 1 and 5% in
599 European-ancestry participants that have $P_{\text{combined}} < 2 \times 10^{-7}$ under an additive genetic model. For *TTN*-rs16866412 and *NOL8*-rs921122, the
600 association is significant ($P < 2 \times 10^{-7}$) upon conditional analysis. The direction of the effect (Beta) and effect allele frequency (AF) is given for the
601 alternate (Alt) allele. For each variant, we provide the most severe annotation using the ENSEMBL Variant Effect Predictor (VEP) tool. N, sample
602 size; Ref, reference allele; SE, standard error

					Discovery (N up to 381,625)				Validation (N up to 252,491)				Combined (N up to 634,116)			
Variant	Chr:Pos	Ref/Alt	Gene	Annotation	AF	Beta	SE	P-value	AF	Beta	SE	P-value	AF	Beta	SE	P-value
rs41292521	1:51873967	G/A	<i>EPSI5</i>	missense	0.020	0.045	0.008	5.07E-08	0.023	0.065	0.010	7.60E-11	0.021	0.053	0.006	2.56E-17
rs61730011	1:119427467	A/C	<i>TBX15</i>	missense	0.042	-0.059	0.006	1.61E-24	0.046	-0.056	0.007	4.19E-15	0.044	-0.058	0.005	2.79E-36
rs11580946	1:150551327	G/A	<i>MCL1</i>	missense	0.014	0.061	0.010	2.16E-09	0.015	0.085	0.012	7.86E-12	0.015	0.070	0.008	1.55E-19
rs141845046	1:154987704	C/T	<i>ZBTB7B</i>	missense	0.028	0.058	0.007	7.30E-17	0.025	0.061	0.010	4.46E-10	0.027	0.059	0.006	3.46E-25
rs79485039	1:180886140	C/T	<i>KIAA1614</i>	missense	0.026	0.034	0.007	1.41E-06	0.031	0.030	0.009	4.51E-04	0.028	0.033	0.006	2.63E-09
rs52826764	2:20205541	C/T	<i>MATN3</i>	missense	0.026	-0.071	0.007	2.67E-23	0.028	-0.084	0.010	6.60E-19	0.027	-0.076	0.006	3.74E-41
rs16859517	2:219949184	C/T	<i>NHEJ1</i>	intron	0.036	0.059	0.006	5.96E-21	0.036	0.064	0.008	1.12E-15	0.036	0.061	0.005	8.20E-37
rs16866412	2:179474668	G/A	<i>TTN</i>	missense	0.013	-0.053	0.010	1.35E-07	0.010	-0.019	0.015	2.15E-01	0.012	-0.042	0.008	3.44E-07
rs7571816	2:233077064	A/G	<i>DIS3L2</i>	intron	0.025	-0.060	0.007	2.35E-16	0.023	-0.079	0.010	2.58E-15	0.024	-0.066	0.006	6.46E-31
rs2229089	3:14214524	G/A	<i>XPC</i>	missense	0.031	-0.038	0.007	1.22E-08	0.035	-0.020	0.008	1.68E-02	0.033	-0.030	0.005	1.29E-08
rs76208147	3:47162886	C/T	<i>SETD2</i>	missense	0.019	0.048	0.009	2.24E-08	0.016	0.062	0.012	2.22E-07	0.018	0.053	0.007	1.65E-13
rs35713889	3:49162583	C/T	<i>LAMB2</i>	missense	0.039	0.043	0.006	3.28E-12	0.045	0.060	0.007	1.33E-16	0.041	0.050	0.005	3.49E-27
rs9838238	3:98600385	T/C	<i>DCBLD2</i>	missense	0.047	0.029	0.005	1.23E-07	0.051	0.027	0.007	5.62E-05	0.048	0.028	0.004	1.68E-12
rs11722554	4:5016883	G/A	<i>CYTL1</i>	missense	0.040	-0.049	0.006	2.01E-17	0.034	-0.057	0.009	6.68E-11	0.038	-0.052	0.005	1.86E-25
rs61730641	4:87730980	C/T	<i>PTPN13</i>	missense	0.015	-0.086	0.010	1.94E-19	0.016	-0.094	0.012	1.38E-15	0.016	-0.089	0.008	9.43E-32
rs116807401	4:135121721	T/C	<i>PABPC4L</i>	missense	0.017	0.065	0.009	1.39E-13	0.016	0.045	0.012	1.33E-04	0.017	0.058	0.007	7.54E-16
rs28925904	4:144359490	C/T	<i>GAB1</i>	missense	0.019	-0.048	0.008	1.04E-08	0.023	-0.036	0.010	3.24E-04	0.021	-0.043	0.006	4.29E-12
rs34343821	4:154557616	C/T	<i>KIAA0922</i>	missense	0.011	0.059	0.011	7.75E-08	0.015	0.056	0.012	5.75E-06	0.013	0.058	0.008	2.18E-12
rs35658696	5:102338811	A/G	<i>PAM</i>	missense	0.048	-0.025	0.005	3.76E-06	0.053	-0.031	0.007	8.47E-06	0.050	-0.027	0.004	1.63E-10
rs34821177	5:126250812	C/T	<i>MARCH3</i>	missense	0.036	0.034	0.006	4.25E-08	0.029	0.027	0.009	2.45E-03	0.034	0.032	0.005	1.67E-10
rs62623707	5:135288632	A/G	<i>LECT2</i>	missense	0.044	-0.030	0.006	1.02E-07	0.049	-0.024	0.007	4.77E-04	0.046	-0.027	0.005	1.36E-09
rs34471628	5:172196752	A/G	<i>DUSP1</i>	missense	0.036	0.048	0.006	4.00E-14	0.042	0.036	0.007	1.26E-06	0.039	0.043	0.005	1.93E-20
rs28932177	5:176637471	G/A	<i>NSD1</i>	missense	0.028	0.063	0.007	2.38E-17	0.027	0.065	0.009	2.62E-12	0.028	0.064	0.006	4.27E-30
rs78247455	5:176722005	G/A	<i>NSD1</i>	missense	0.023	-0.083	0.008	1.86E-26	0.025	-0.085	0.010	8.42E-18	0.024	-0.084	0.006	2.32E-41
rs7757648	6:30851933	G/A	<i>DDR1</i>	intron	0.013	-0.075	0.013	1.11E-08	0.011	-0.079	0.018	1.24E-05	0.012	-0.076	0.011	4.64E-13
rs34427075	6:34730395	C/T	<i>SNRPC</i>	synonymous	0.014	-0.117	0.010	9.21E-33	0.016	-0.139	0.012	9.59E-31	0.015	-0.126	0.008	3.45E-60
rs33966734	6:41903798	C/A	<i>CCND3</i>	stop_gained	0.013	-0.140	0.017	5.51E-17	0.011	-0.101	0.018	3.41E-08	0.012	-0.122	0.012	1.28E-22
rs17277546	7:99489571	G/A	<i>TRIM4</i>	3'UTR	0.049	0.034	0.005	3.28E-10	0.052	0.038	0.007	2.26E-07	0.050	0.035	0.004	1.40E-17
rs7636	7:100490077	G/A	<i>ACHE</i>	synonymous	0.043	-0.037	0.006	8.59E-10	0.035	-0.019	0.009	2.92E-02	0.040	-0.031	0.005	2.98E-10
rs17480616	7:135123060	G/C	<i>CNOT4</i>	missense	0.028	0.060	0.007	2.31E-17	0.030	0.054	0.009	5.04E-10	0.029	0.058	0.005	3.90E-26
rs3136797	8:42226805	C/G	<i>POLB</i>	missense	0.018	0.044	0.009	1.95E-06	0.021	0.026	0.010	1.30E-02	0.019	0.036	0.007	1.88E-07
rs11575580	9:34660864	C/T	<i>IL11RA</i>	missense	0.016	-0.064	0.009	5.20E-13	0.020	-0.030	0.011	4.42E-03	0.018	-0.050	0.007	4.01E-13
rs921122	9:95063947	C/T	<i>NOL8</i>	missense	0.039	0.041	0.009	2.56E-06	0.040	0.018	0.008	3.45E-02	0.040	0.029	0.006	3.33E-06

rs41274586	10:79580976	G/A	<i>DLG5</i>	missense	0.017	-0.058	0.009	2.72E-11	0.017	-0.076	0.012	5.15E-11	0.017	-0.065	0.007	7.66E-20
rs41291604	10:97919011	A/G	<i>ZNF518A</i>	missense	0.040	0.031	0.006	9.94E-08	0.040	0.022	0.008	3.05E-03	0.040	0.028	0.005	3.91E-09
rs71455793	11:65715204	G/A	<i>TSGA10IP</i>	missense	0.039	-0.058	0.006	1.82E-21	0.046	-0.072	0.007	1.41E-23	0.042	-0.064	0.005	1.52E-43
rs4072796	12:7548996	C/G	<i>CD163L1</i>	missense	0.035	0.034	0.006	4.11E-08	0.037	0.015	0.008	6.68E-02	0.036	0.027	0.005	1.87E-08
rs61743810	12:69140339	G/C	<i>SLC35E3</i>	missense	0.022	-0.047	0.008	1.13E-09	0.023	-0.036	0.010	5.11E-04	0.022	-0.043	0.006	1.29E-11
rs117801489	12:104408832	T/C	<i>GLT8D2</i>	missense	0.017	0.053	0.009	8.72E-10	0.028	0.062	0.010	5.82E-10	0.022	0.057	0.007	1.60E-17
rs2066674	13:50842259	G/A	<i>DLEU1</i>	intron	0.044	0.073	0.006	2.33E-37	0.041	0.084	0.008	7.02E-25	0.043	0.077	0.005	5.66E-57
rs17880989	14:23313633	G/A	<i>MMP14</i>	missense	0.027	0.041	0.007	1.72E-08	0.029	0.052	0.009	7.81E-09	0.028	0.045	0.006	3.27E-16
rs34354104	14:24707479	G/A	<i>GMPT2</i>	missense	0.048	0.045	0.005	3.67E-16	0.050	0.047	0.007	1.34E-11	0.049	0.046	0.004	2.13E-29
rs117295933	14:45403699	C/A	<i>KLHL28</i>	missense	0.016	-0.045	0.009	1.55E-06	0.025	-0.036	0.010	4.13E-04	0.020	-0.041	0.007	3.05E-09
rs41286548	14:70633411	C/T	<i>SLC8A3</i>	missense	0.021	-0.054	0.008	2.49E-11	0.026	-0.045	0.009	2.02E-06	0.023	-0.050	0.006	2.03E-16
rs28929474	14:94844947	C/T	<i>SERPINA1</i>	missense	0.018	0.124	0.009	1.39E-45	0.019	0.139	0.011	2.50E-34	0.019	0.130	0.007	1.72E-75
rs41286560	14:101349454	G/T	<i>RTL1</i>	missense	0.024	-0.050	0.007	1.17E-11	0.028	-0.033	0.009	2.12E-04	0.026	-0.044	0.006	2.50E-15
rs116858574	15:34520687	T/C	<i>EMC4</i>	missense	0.014	0.047	0.010	1.16E-06	0.014	0.028	0.012	2.19E-02	0.014	0.040	0.008	1.60E-07
rs34815962	15:72462255	C/T	<i>GRAMD2</i>	missense	0.019	0.073	0.009	8.72E-17	0.023	0.074	0.010	3.66E-13	0.021	0.073	0.007	1.28E-27
rs16942341	15:89388905	C/T	<i>ACAN</i>	synonymous	0.026	-0.129	0.007	4.30E-72	0.028	-0.146	0.009	1.08E-56	0.027	-0.135	0.006	3.79E-130
rs61733564	16:4812705	A/G	<i>ZNF500</i>	missense	0.032	0.056	0.007	8.61E-17	0.032	0.044	0.009	2.34E-07	0.032	0.051	0.005	2.89E-21
rs113388806	16:24804954	A/T	<i>TNRC6A</i>	missense	0.040	0.036	0.006	1.08E-09	0.047	0.041	0.008	1.65E-07	0.043	0.038	0.005	1.90E-15
rs8052655	16:67409180	G/A	<i>LRRC36</i>	missense	0.043	-0.054	0.006	1.08E-18	0.043	-0.055	0.008	3.91E-13	0.043	-0.054	0.005	6.40E-31
rs77542162	17:67081278	A/G	<i>ABCA6</i>	missense	0.017	0.049	0.010	2.17E-06	0.023	0.051	0.010	5.58E-07	0.020	0.050	0.007	5.57E-12
rs77169818	18:74980601	A/T	<i>GALR1</i>	missense	0.047	-0.048	0.006	3.60E-18	0.038	-0.035	0.008	3.64E-05	0.044	-0.044	0.005	5.11E-19
rs3208856	19:45296806	C/T	<i>CBLC</i>	missense	0.034	0.036	0.007	1.48E-07	0.034	0.021	0.008	1.19E-02	0.034	0.030	0.005	2.96E-08
rs4252548	19:55879672	C/T	<i>IL11</i>	missense	0.026	-0.114	0.007	1.02E-57	0.022	-0.101	0.010	2.28E-23	0.025	-0.110	0.006	5.32E-81
rs147110934	19:55993436	G/T	<i>ZNF628</i>	missense	0.021	-0.084	0.010	2.28E-18	0.022	-0.098	0.011	1.17E-18	0.022	-0.090	0.007	6.33E-34
rs77885044	22:28501414	C/T	<i>TTC28</i>	missense	0.012	-0.067	0.010	9.47E-11	0.017	-0.069	0.012	3.24E-09	0.014	-0.068	0.008	3.93E-19
rs147348682	22:42095658	T/G	<i>MEI1</i>	missense	0.025	0.041	0.007	2.25E-08	0.034	0.024	0.009	6.59E-03	0.029	0.034	0.006	3.70E-10

603

604 **Table 3.** Ten height genes implicated by gene-based testing. These genes meet our three criteria for statistical significance: (1) gene-based $P < 2 \times 10^{-6}$,
 605 (2) the gene does not include variants with $P < 2 \times 10^{-7}$, and (3) the gene-based P-value is at least two orders of magnitude smaller than the P-value for
 606 the most significant variant within the gene. For each gene, we provide P-values for the four different gene-based tests applied. P-values in bold are
 607 the most significant results for a given gene. ¹Replication results using the same test and (when possible) variants in 59,804 European-ancestry
 608 individuals. ²When the gene is located in a locus identified by our single-variant analysis (1 Mb window), we conditioned the gene-based association
 609 result by genotypes at the single variant. ³If the gene falls within a known GWAS height locus, we mention if it was predicted to be causal using
 610 bioinformatic tools (ref. ³). NA, not applicable.

611

Gene	Discovery gene-based P-value				Replication P-value ¹	Conditional P-value ²	Note ³
	SKAT-broad	VT-broad	SKAT-strict	VT-strict			
<i>OSGIN1</i>	4.3x10⁻¹¹	4.5x10 ⁻⁵	0.19	0.18	0.048	7.7x10 ⁻¹¹	Known locus. No predicted causal genes.
<i>CRISPLD1</i>	2.2x10 ⁻⁷	1.5x10⁻¹⁰	8.5x10 ⁻⁶	8.9x10 ⁻⁷	0.50	NA	Known locus, sentinel GWAS SNP not tested on ExomeChip. <i>CRISPLD1</i> was predicted to be causal.
<i>CSAD</i>	2.3x10 ⁻⁸	6.0x10⁻¹⁰	0.83	0.59	0.54	NA	New locus.
<i>SNED1</i>	1.9x10 ⁻⁵	2.3x10⁻⁹	NA	NA	0.083	1.4x10 ⁻⁹	Known locus. <i>SNED1</i> was not predicted to be causal.
<i>G6PC</i>	1.3x10 ⁻⁵	3.6x10⁻⁸	5.5x10 ⁻⁶	1.3x10 ⁻⁶	0.24	3.9x10 ⁻⁸	Known locus, <i>G6PC</i> was not predicted to be causal. <i>G6PC</i> is mutated in glycogen storage disease Ia.
<i>NOX4</i>	5.1x10 ⁻⁶	1.8x10⁻⁷	NA	NA	0.013	NA	New locus.
<i>UGGT2</i>	3.0x10 ⁻⁵	2.0x10⁻⁷	2.3x10 ⁻⁵	4.8x10 ⁻⁷	0.64	NA	New locus.
<i>FLNB</i>	2.2x10 ⁻⁶	5.1x10 ⁻⁴	2.4x10⁻⁹	3.2x10 ⁻⁶	0.016	3.6x10 ⁻⁹	Known locus. <i>FLNB</i> was predicted to be causal. <i>FLNB</i> is mutated in atelosteogenesis type I.
<i>B4GALNT3</i>	2.4x10 ⁻⁵	1.9x10 ⁻⁵	1.8x10 ⁻⁵	3.4x10⁻⁷	0.79	7.7x10 ⁻⁷	Known locus. <i>B4GALNT3</i> was predicted to be causal.
<i>CCDC3</i>	6.3x10 ⁻⁴	6.3x10 ⁻⁶	3.0x10 ⁻⁷	5.5x10⁻⁹	0.080	1.6x10 ⁻⁹	Known locus. <i>CCDC3</i> was predicted to be causal.

612

Figure legends

Figure 1. Variants with a larger effect size on height variation tend to be rarer. We observe an inverse relationship between the effect size (from the combined “discovery+ validation” analysis, in cm on the y-axis) and the minor allele frequency (MAF) for the height variants (x-axis, from 0 to 50%). We included in this figure the 606 height variants with $P < 2 \times 10^{-7}$.





Figure 2. Heat map showing subset of DEPICT gene set enrichment results. The full heat map is available as **Supplementary Fig. 13**. For any given square, the color indicates how strongly the corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted gene set (y-axis). This value is based on the gene's Z-score for gene set inclusion in DEPICT's reconstituted gene sets, where red indicates a higher Z-score and blue indicates a lower one. The proteoglycan binding pathway (bold) was uniquely implicated by coding variants (as opposed to common variants) by both DEPICT and the PASCAL method. To visually reduce redundancy and increase clarity, we chose one representative "meta-gene set" for each group of highly correlated gene sets based on affinity propagation clustering (**Supplementary Note**). Heat map intensity and DEPICT P-values correspond to the most significantly enriched gene set within the meta-gene set; meta-gene sets are listed with their database source. Annotations for the genes indicate whether the gene has OMIM annotation as underlying a disorder of skeletal growth (black and grey) and the minor allele frequency of the significant ExomeChip (EC) variant (shades of blue; if multiple variants, the lowest-frequency variant was kept). Annotations for the gene sets indicate if the gene set was also found significant for EC by the PASCAL method (yellow and grey) and if the gene set was found significant by DEPICT for EC only or for both EC and GWAS (purple and green). Abbreviations: GO: Gene Ontology; MP: mouse phenotype in the Mouse Genetics Initiative; PPI: protein-protein interaction in the InWeb database.

641 (Figure 2)




642

643

Figure 3. STC2 mutants p.Arg44Leu (R44L) and p.Met86Ile (M86I) show compromised proteolytic inhibition of PAPP-A. **(A)** Schematic representation of the role of STC2 in IGF-1 signaling. Partial inactivation of STC2 by height-associated DNA sequence variation could increase bioactive IGF-1 through reduced inhibition of PAPP-A. **(B)** Western blot analysis of recombinant STC2 wild-type and variants R44L and M86I. **(C)** Covalent complex formation between PAPP-A and STC2 wild-type or variants R44L and M86I. Separately synthesized proteins were analyzed by PAPP-A Western blotting following incubation for 8 h. In the absence of STC2 (Mock lane), PAPP-A appears as a single 400 kDa band (*). Following incubation with wild-type STC2, the majority of PAPP-A is present as the approximately 500 kDa covalent PAPP-A:STC2 complex (#), in which PAPP-A is devoid of proteolytic activity towards IGFBP-4. Under similar conditions, incubation with variants R44L or M86I appeared to cause less covalent complex formation with PAPP-A. The gels are representative of at least three independent experiments. **(D)** PAPP-A proteolytic cleavage of IGFBP-4 following incubation with wild-type STC2 or variants for 1-24 h. Wild-type STC2 causes reduction in PAPP-A activity, with complete inhibition of activity following 24 h incubation. Both STC2 variants show increased IGFBP-4 cleavage (*i.e.* less inhibition) for all time points analyzed. Mean and standard deviations of three independent experiments are shown. One-way repeated measures analysis of variance followed by Dunnett's post-test showed significant differences between STC2 wild-type and variants R44L ($P<0.001$) and M86I ($P<0.01$).

665 (Figure 3)



666

References

- 1 Fisher, R. A. The Correlation Between Relatives on the Supposition of Mendelian Inheritance. *Transactions of the Royal Society of Edinburgh* **52**, 399-433 (1918).
- 2 Silventoinen, K. *et al.* Heritability of adult body height: a comparative study of twin cohorts in eight countries. *Twin research : the official journal of the International Society for Twin Studies* **6**, 399-408, doi:10.1375/136905203770326402 (2003).
- 3 Wood, A. R. *et al.* Defining the role of common variation in the genomic and biological architecture of adult human height. *Nat Genet* **46**, 1173-1186, doi:10.1038/ng.3097 (2014).
- 4 Flannick, J. *et al.* Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. *Nat Genet* **46**, 357-363, doi:10.1038/ng.2915 (2014).
- 5 Steinthorsdottir, V. *et al.* Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. *Nat Genet* **46**, 294-298, doi:10.1038/ng.2882 (2014).
- 6 Gudmundsson, J. *et al.* A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. *Nat Genet* **44**, 1326-1329, doi:10.1038/ng.2437 (2012).
- 7 Sidore, C. *et al.* Genome sequencing elucidates Sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers. *Nat Genet* **47**, 1272-1281, doi:10.1038/ng.3368 (2015).
- 8 Danjou, F. *et al.* Genome-wide association analyses based on whole-genome sequencing in Sardinia provide insights into regulation of hemoglobin levels. *Nat Genet* **47**, 1264-1271, doi:10.1038/ng.3307 (2015).

690 9 Zuk, O. *et al.* Searching for missing heritability: designing rare variant association
691 studies. *Proc Natl Acad Sci U S A* **111**, E455-464, doi:10.1073/pnas.1322563111
692 (2014).

693 10 Yang, J. *et al.* Genetic variance estimation with imputed variants finds negligible
694 missing heritability for human height and body mass index. *Nat Genet* **47**, 1114-
695 1120, doi:10.1038/ng.3390 (2015).

696 11 Grove, M. L. *et al.* Best practices and joint calling of the HumanExome BeadChip:
697 the CHARGE Consortium. *PloS one* **8**, e68095, doi:10.1371/journal.pone.0068095
698 (2013).

699 12 Wu, M. C. *et al.* Rare-variant association testing for sequencing data with the
700 sequence kernel association test. *Am J Hum Genet* **89**, 82-93,
701 doi:10.1016/j.ajhg.2011.05.029 (2011).

702 13 Pers, T. H. *et al.* Biological interpretation of genome-wide association studies using
703 predicted gene functions. *Nat Commun* **6**, 5890, doi:10.1038/ncomms6890 (2015).

704 14 Lamparter, D., Marbach, D., Rueedi, R., Kutalik, Z. & Bergmann, S. Fast and
705 Rigorous Computation of Gene and Pathway Scores from SNP-Based Summary
706 Statistics. *PLoS Comput Biol* **12**, e1004714, doi:10.1371/journal.pcbi.1004714
707 (2016).

708 15 Schwartz, N. B. & Domowicz, M. Chondrodysplasias due to proteoglycan defects.
709 *Glycobiology* **12**, 57R-68R (2002).

710 16 Wei, H. S., Wei, H. L., Zhao, F., Zhong, L. P. & Zhan, Y. T. Glycosyltransferase
711 GLT8D2 positively regulates ApoB100 protein expression in hepatocytes. *Int J Mol*
712 *Sci* **14**, 21435-21446, doi:10.3390/ijms141121435 (2013).

713 17 Ito, H. *et al.* Molecular cloning and biological activity of a novel lysyl oxidase-
714 related gene expressed in cartilage. *J Biol Chem* **276**, 24023-24029,
715 doi:10.1074/jbc.M100861200 (2001).

716 18 Wakahara, T. *et al.* Fibin, a novel secreted lateral plate mesoderm signal, is essential
717 for pectoral fin bud initiation in zebrafish. *Dev Biol* **303**, 527-535,
718 doi:10.1016/j.ydbio.2006.11.041 (2007).

719 19 Kawano, Y. & Kypta, R. Secreted antagonists of the Wnt signalling pathway. *J Cell*
720 *Sci* **116**, 2627-2634, doi:10.1242/jcs.00623 (2003).

721 20 Mastaitis, J. *et al.* Loss of SFRP4 Alters Body Size, Food Intake, and Energy
722 Expenditure in Diet-Induced Obese Male Mice. *Endocrinology* **156**, 4502-4510,
723 doi:10.1210/en.2015-1257 (2015).

724 21 Jepsen, M. R. *et al.* Stanniocalcin-2 inhibits mammalian growth by proteolytic
725 inhibition of the insulin-like growth factor axis. *J Biol Chem* **290**, 3430-3439,
726 doi:10.1074/jbc.M114.611665 (2015).

727 22 Dauber, A. *et al.* Mutations in pregnancy-associated plasma protein A2 cause short
728 stature due to low IGF-I availability. *EMBO Mol Med*,
729 doi:10.15252/emmm.201506106 (2016).

730 23 Lango Allen, H. *et al.* Hundreds of variants clustered in genomic loci and biological
731 pathways affect human height. *Nature* **467**, 832-838, doi:nature09410 [pii]
732 10.1038/nature09410 (2010).

733 24 Pickrell, J. K. *et al.* Detection and interpretation of shared genetic influences on 42
734 human traits. *Nat Genet* **48**, 709-717, doi:10.1038/ng.3570 (2016).

735 25 Park, J. H. *et al.* SLC39A8 Deficiency: A Disorder of Manganese Transport and
736 Glycosylation. *Am J Hum Genet* **97**, 894-903, doi:10.1016/j.ajhg.2015.11.003
737 (2015).

738 26 Boycott, K. M. *et al.* Autosomal-Recessive Intellectual Disability with Cerebellar
739 Atrophy Syndrome Caused by Mutation of the Manganese and Zinc Transporter
740 Gene SLC39A8. *Am J Hum Genet* **97**, 886-893, doi:10.1016/j.ajhg.2015.11.002
741 (2015).

742 27 Ehret, G. B. *et al.* Genetic variants in novel pathways influence blood pressure and
743 cardiovascular disease risk. *Nature* **478**, 103-109, doi:10.1038/nature10405 (2011).

744 28 Willer, C. J. *et al.* Discovery and refinement of loci associated with lipid levels.
745 *Nature genetics* **45**, 1274-1283, doi:10.1038/ng.2797 (2013).

746 29 Speliotes, E. K. *et al.* Association analyses of 249,796 individuals reveal 18 new
747 loci associated with body mass index. *Nature genetics* **42**, 937-948,
748 doi:10.1038/ng.686 (2010).

749 30 Wain, L. V. *et al.* Genome-wide association study identifies six new loci
750 influencing pulse pressure and mean arterial pressure. *Nature genetics* **43**, 1005-
751 1011, doi:10.1038/ng.922 (2011).

752 31 Bartlett, J. R. *et al.* Genetic modifiers of liver disease in cystic fibrosis. *Jama* **302**,
753 1076-1083, doi:10.1001/jama.2009.1295 (2009).

754 32 North, T. L. *et al.* A study of common Mendelian disease carriers across ageing
755 British cohorts: meta-analyses reveal heterozygosity for alpha 1-antitrypsin
756 deficiency increases respiratory capacity and height. *J Med Genet* **53**, 280-288,
757 doi:10.1136/jmedgenet-2015-103342 (2016).

758 33 Karaplis, A. C. *et al.* Inactivating mutation in the human parathyroid hormone
759 receptor type 1 gene in Blomstrand chondrodysplasia. *Endocrinology* **139**, 5255-
760 5258, doi:10.1210/endo.139.12.6522 (1998).

761 34 Sims, N. A. *et al.* Interleukin-11 receptor signaling is required for normal bone
762 remodeling. *J Bone Miner Res* **20**, 1093-1102, doi:10.1359/JBMR.050209 (2005).

763 35 Takeuchi, Y. *et al.* Interleukin-11 as a stimulatory factor for bone formation
764 prevents bone loss with advancing age in mice. *J Biol Chem* **277**, 49011-49018,
765 doi:10.1074/jbc.M207804200 (2002).

766 36 Goldstein, J. I. *et al.* zCall: a rare variant caller for array-based genotyping: genetics
767 and population analysis. *Bioinformatics* **28**, 2543-2545,
768 doi:10.1093/bioinformatics/bts479 (2012).

769 37 Liu, D. J. *et al.* Meta-analysis of gene-level tests for rare variant association. *Nat*
770 *Genet* **46**, 200-204, doi:10.1038/ng.2852 (2014).

771 38 Winkler, T. W. & Day, F. R. Quality control and conduct of genome-wide
772 association meta-analyses. **9**, 1192-1212, doi:10.1038/nprot.2014.071 (2014).

773 39 Purcell, S. M. *et al.* A polygenic burden of rare disruptive mutations in
774 schizophrenia. *Nature* **506**, 185-190, doi:10.1038/nature12975 (2014).

775 40 Price, A. L. *et al.* Pooled association tests for rare variants in exon-resequencing
776 studies. *Am J Hum Genet* **86**, 832-838, doi:10.1016/j.ajhg.2010.04.005 (2010).

777 41 Yang, J. *et al.* Genomic inflation factors under polygenic inheritance. *European*
778 *Journal of Human Genetics* **19**, 807-812, doi:10.1038/ejhg.2011.39 (2011).

779 42 Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from
780 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-295,
781 doi:10.1038/ng.3211 (2015).

782 43 Feng, S., Liu, D., Zhan, X., Wing, M. K. & Abecasis, G. R. RAREMETAL: fast
783 and powerful meta-analysis for rare variants. *Bioinformatics (Oxford, England)* **30**,
784 2828-2829, doi:10.1093/bioinformatics/btu367 (2014).

785 44 Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary
786 statistics identifies additional variants influencing complex traits. *Nature genetics*
787 **44**, 369-S363, doi:10.1038/ng.2213 (2012).

788 45 Loh, P. R. *et al.* Efficient Bayesian mixed-model analysis increases association
789 power in large cohorts. *Nat Genet* **47**, 284-290, doi:10.1038/ng.3190 (2015).

790 46 Pasaniuc, B. *et al.* Fast and accurate imputation of summary statistics enhances
791 evidence of functional enrichment. *Bioinformatics* **30**, 2906-2914,
792 doi:10.1093/bioinformatics/btu416 (2014).

793 47 Moayyeri, A., Hammond, C. J., Valdes, A. M. & Spector, T. D. Cohort Profile:
794 TwinsUK and healthy ageing twin study. *Int J Epidemiol* **42**, 76-85,
795 doi:10.1093/ije/dyr207 (2013).

796 48 Boyd, A. *et al.* Cohort Profile: the 'children of the 90s'--the index offspring of the
797 Avon Longitudinal Study of Parents and Children. *Int J Epidemiol* **42**, 111-127,
798 doi:10.1093/ije/dys064 (2013).

799 49 Fehrmann, R. S. *et al.* Gene expression analysis identifies global gene dosage
800 sensitivity in cancer. *Nat Genet* **47**, 115-125, doi:10.1038/ng.3173 (2015).

801 50 Frey, B. J. & Dueck, D. Clustering by passing messages between data points.
802 *Science* **315**, 972-976, doi:10.1126/science.1136800 (2007).

803 51 Willer, C. J., Li, Y. & Abecasis, G. R. METAL: Fast and efficient meta-analysis of
804 genomewide association scans. *Bioinformatics* **26**, 2190-2191, doi:btq340 [pii]
805 10.1093/bioinformatics/btq340 (2010).

- Overgaard, M. T. *et al.* Expression of recombinant human pregnancy-associated plasma protein-A and identification of the proform of eosinophil major basic protein as its physiological inhibitor. *The Journal of biological chemistry* **275**, 31128-31133, doi:10.1074/jbc.M001384200 (2000).
- Gyruv, C. & Oxvig, C. Quantitative analysis of insulin-like growth factor-modulated proteolysis of insulin-like growth factor binding protein-4 and -5 by pregnancy-associated plasma protein-A. *Biochemistry* **46**, 1972-1980, doi:10.1021/bi062229i (2007).
- Oxvig, C., Sand, O., Kristensen, T., Kristensen, L. & Sottrup-Jensen, L. Isolation and characterization of circulating complex between human pregnancy-associated plasma protein-A and proform of eosinophil major basic protein. *Biochimica et biophysica acta* **1201**, 415-423 (1994).
- Nikpay, M. *et al.* A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* **47**, 1121-1130, doi:10.1038/ng.3396 (2015).

823 Authors

824
825 Eirini Marouli^{1*}, Mariaelisa Graff^{2*}, Carolina Medina-Gomez^{3, 4*}, Ken Sin Lo^{5*}, Andrew
826 R Wood^{6*}, Troels R Kjaer^{7*}, Rebecca S Fine^{8-10*}, Yingchang Lu^{11-13*}, Claudia
827 Schurmann^{12, 13}, Heather M Highland^{2, 14}, Sina Rüeger^{15, 16}, Gudmar Thorleifsson¹⁷, Anne E
828 Justice², David Lamparter^{16, 18}, Kathleen E Stirrups^{1, 19}, Valérie Turcot⁵, Kristin L Young²,
829 Thomas W Winkler²⁰, Tõnu Esko^{8, 10, 21}, Tugce Karaderi²², Adam E Locke^{23, 24}, Nicholas
830 GD Masca^{25, 26}, Maggie CY Ng^{27, 28}, Poorva Mudgal²⁷, Manuel A Rivas^{8, 29}, Sailaja
831 Vedantam⁸⁻¹⁰, Anubha Mahajan²², Katja K Aben^{30, 31}, Linda S Adair³², Dewan S Alam³³,
832 Eva Albrecht³⁴, Kristine H Allin³⁵, Matthew Allison³⁶, Philippe Amouyel³⁷⁻³⁹, Emil V
833 Appel³⁵, Dominique Arveiler^{40, 41}, Folkert W Asselbergs⁴²⁻⁴⁴, Paul L Auer⁴⁵, Beverley
834 Balkau⁴⁶, Bernhard Banas⁴⁷, Lia E Bang⁴⁸, Marianne Benn^{49, 50}, Sven Bergmann^{16, 18},
835 Lawrence F Bielak⁵¹, Matthias Blüher^{52, 53}, Heiner Boeing⁵⁴, Eric Boerwinkle^{55, 56}, Carsten
836 A Böger^{20, 47}, Lori L Bonnycastle⁵⁷, Jette Bork-Jensen³⁵, Michiel L Bots⁵⁸, Erwin P
837 Bottinger¹², Donald W Bowden^{27, 28, 59}, Ivan Brandslund^{60, 61}, Gerome Breen⁶², Murray H
838 Brilliant⁶³, Linda Broer⁴, Amber A Burt⁶⁴, Adam S Butterworth^{65, 66}, David J Carey⁶⁷, Mark
839 J Caulfield^{1, 68}, John C Chambers⁶⁹⁻⁷¹, Daniel I Chasman⁷²⁻⁷⁴, Yii-Der Ida Chen⁷⁵, Rajiv
840 Chowdhury⁶⁵, Cramer Christensen⁷⁶, Audrey Y Chu^{73, 77}, Massimiliano Cocca⁷⁸, Francis S
841 Collins⁵⁷, James P Cook⁷⁹, Janie Corley^{80, 81}, Jordi Corominas Galbany⁸², Amanda J Cox^{27,}
842 ^{28, 83}, Gabriel Cuellar-Partida^{84, 85}, John Danesh^{65, 66, 86}, Gail Davies^{80, 81}, Paul IW de
843 Bakker^{87, 88}, Gert Jan de Borst⁸⁹, Simon de Denus^{5, 90}, Mark CH de Groot^{91, 92}, Renée de
844 Mutsert⁹³, Ian J Deary^{80, 81}, George Dedoussis⁹⁴, Ellen W Demerath⁹⁵, Anneke I den
845 Hollander⁹⁶, Joe G Dennis⁹⁷, Emanuele Di Angelantonio^{65, 66}, Fotios Drenos^{98, 99},
846 Mengmeng Du^{100, 101}, Alison M Dunning¹⁰², Douglas F Easton^{97, 102}, Tapani Ebeling^{103, 104},
847 Todd L Edwards¹⁰⁵, Patrick T Ellinor^{106, 107}, Paul Elliott¹⁰⁸, Evangelos Evangelou^{70, 109},
848 Aliko-Eleni Farmaki⁹⁴, Jessica D Faul¹¹⁰, Mary F Feitosa¹¹¹, Shuang Feng¹¹², Ele
849 Ferrannini^{113, 114}, Marco M Ferrario¹¹⁵, Jean Ferrieres¹¹⁶, Ian Ford¹¹⁷, Myriam Fornage¹¹⁸,
850 Paul W Franks¹¹⁹⁻¹²¹, Ruth Frikke-Schmidt^{50, 122}, Tessel E Galesloot³¹, Wei Gan²², Ilaria
851 Gandin¹²³, Paolo Gasparini^{123, 124}, Vilmantas Giedraitis¹²⁵, Ayush Giri¹⁰⁵, Giorgia
852 Girotto^{123, 124}, Scott D Gordon⁸⁵, Penny Gordon-Larsen^{126, 127}, Mathias Gorski^{20, 47}, Niels
853 Grarup³⁵, Megan L. Grove⁵⁵, Vilmundur Gudnason^{128, 129}, Xiuqing Guo⁷⁵, Stefan
854 Gustafsson¹³⁰, Torben Hansen³⁵, Kathleen M Harris^{126, 131}, Tamara B Harris¹³², Andrew T
855 Hattersley¹³³, Caroline Hayward¹³⁴, Liang He^{135, 136}, Iris M Heid^{20, 34}, Kauko Heikkilä^{136,}
856 ¹³⁷, Øyvind Helgeland^{138, 139}, Jussi Hernesniemi¹⁴⁰⁻¹⁴², Alex W Hewitt¹⁴³⁻¹⁴⁵, Lynne J
857 Hocking^{146, 147}, Mette Hollensted³⁵, Oddgeir L Holmen¹⁴⁸, G. Kees Hovingh¹⁴⁹, Joanna MM
858 Howson⁶⁵, Carel B Hoyng⁹⁶, Paul L Huang¹⁰⁶, Kristian Hveem¹⁵⁰, M. Arfan Ikram^{3, 151, 152},
859 Erik Ingelsson^{130, 153}, Anne U Jackson¹¹², Jan-Håkan Jansson^{154, 155}, Gail P Jarvik^{64, 156},
860 Gorm B Jensen¹⁵⁷, Min A Jhun⁵¹, Yucheng Jia⁷⁵, Xuejuan Jiang^{158, 159}, Stefan Johansson^{139,}
861 ¹⁶⁰, Marit E Jørgensen^{161, 162}, Torben Jørgensen^{50, 163, 164}, Pekka Jousilahti¹⁶⁵, J Wouter
862 Jukema^{166, 167}, Bratati Kahali¹⁶⁸⁻¹⁷⁰, René S Kahn¹⁷¹, Mika Kähönen¹⁷², Pia R Kamstrup^{49, 50},
863 Stavroula Kanoni¹, Jaakko Kaprio^{136, 137, 173}, Maria Karaleftheri¹⁷⁴, Sharon LR Kardina⁵¹,
864 Fredrik Karpe^{175, 176}, Frank Kee¹⁷⁷, Renske Keeman¹⁷⁸, Lambertus A Kiemeny³¹,
865 Hidetoshi Kitajima²², Kirsten B Kluivers³¹, Thomas Kocher¹⁷⁹, Pirjo Komulainen¹⁸⁰, Jukka
866 Kontto¹⁷³, Jaspal S Kooner^{69, 71, 181}, Charles Kooperberg¹⁸², Peter Kovacs⁵², Jennifer
867 Kriebel¹⁸³⁻¹⁸⁵, Helena Kuivaniemi^{67, 186}, Sébastien Küry¹⁸⁷, Johanna Kuusisto¹⁸⁸, Martina
868 La Bianca¹⁸⁹, Markku Laakso¹⁸⁸, Timo A Lakka^{180, 190}, Ethan M Lange¹⁹¹, Leslie A
869 Lange¹⁹¹, Carl D Langefeld¹⁹², Claudia Langenberg¹⁹³, Eric B Larson^{64, 194, 195}, I-Te Lee¹⁹⁶,

870 ¹⁹⁷, Terho Lehtimäki^{141, 142}, Cora E Lewis¹⁹⁸, Huaixing Li¹⁹⁹, Jin Li²⁰⁰, Ruifang Li-Gao⁹³,
 871 Honghuang Lin²⁰¹, Li-An Lin¹¹⁸, Xu Lin¹⁹⁹, Lars Lind²⁰², Jaana Lindström²⁰³, Allan
 872 Linneberg²⁰³, Yeheng Liu⁷⁵, Yongmei Liu²⁰⁴, Artitaya Lophatananon²⁰⁵, Jian'an Luan¹⁹³,
 873 Steven A Lubitz^{106, 107}, Leo-Pekka Lyytikäinen^{141, 142}, David A Mackey¹⁴⁴, Pamela AF
 874 Madden²⁰⁶, Alisa K Manning^{106, 107, 207}, Satu Männistö¹⁷³, Gaëlle Marenne⁸⁶, Jonathan
 875 Marten¹³⁴, Nicholas G Martin⁸⁵, Angela L Mazul², Karina Meidtner^{183, 208}, Andres
 876 Metspalu²¹, Paul Mitchell²⁰⁹, Karen L Mohlke¹⁹¹, Dennis O Mook-Kanamori^{93, 210}, Anna
 877 Morgan¹²³, Andrew D Morris²¹¹, Andrew P Morris^{22, 79}, Martina Müller-Nurasyid^{34, 212, 213},
 878 Patricia B Munroe^{1, 68}, Mike A Nalls²¹⁴, Matthias Nauck^{215, 216}, Christopher P Nelson^{25, 26},
 879 Matt Neville^{175, 176}, Sune F Nielsen^{49, 50}, Kjell Nikus²¹⁷, Pål R Njølstad^{138, 139}, Børge G
 880 Nordestgaard^{49, 50}, Ioanna Ntalla¹, Jeffrey R O'Connell²¹⁸, Heikki Oksa²¹⁹, Loes M Olde
 881 Loohuis²²⁰, Roel A Ophoff^{171, 220}, Katharine R Owen^{175, 176}, Chris J Packard¹¹⁷, Sandosh
 882 Padmanabhan¹¹⁷, Colin NA Palmer²²¹, Gerard Pasterkamp^{222, 223}, Aniruddh P Patel^{8, 74, 106},
 883 Alison Pattie⁸¹, Oluf Pedersen³⁵, Peggy L Peissig⁶³, Craig E Pennell²²⁴, Markus Perola^{173,}
 884 ^{225, 226}, James A Perry²¹⁸, Thomas N Person⁶³, Ailith Pirie¹⁰², Ozren Polasek^{211, 227}, Danielle
 885 Posthuma^{228, 229}, Olli T Raitakari^{230, 231}, Asif Rasheed²³², Rainer Rauramaa^{180, 233}, Dermot F
 886 Reilly²³⁴, Alex P Reiner^{182, 235}, Frida Renström^{119, 236}, Paul M Ridker^{73, 74, 237}, John D
 887 Rioux^{5, 238}, Neil Robertson^{22, 175}, Antonietta Robino¹⁸⁹, Olov Rolandsson^{154, 239}, Igor
 888 Rudan²¹¹, Danish Saleheen^{232, 240}, Veikko Salomaa¹⁷³, Nilesh J Samani^{25, 26}, Kevin
 889 Sandow⁷⁵, Yadav Sapkota⁸⁵, Naveed Sattar¹¹⁷, Marjanka K Schmidt¹⁷⁸, Pamela J
 890 Schreiner²⁴¹, Matthias B Schulze^{183, 208}, Robert A Scott¹⁹³, Marcelo P Segura-Lepe⁷⁰, Svati
 891 Shah²⁴², Xueling Sim^{112, 243}, Suthesh Sivapalaratnam^{106, 244, 245}, Kerrin S Small²⁴⁶, Albert
 892 Vernon Smith^{128, 129}, Jennifer A Smith⁵¹, Lorraine Southam^{22, 86}, Timothy D Spector²⁴⁶,
 893 Elizabeth K Speliotes¹⁶⁸⁻¹⁷⁰, John M Starr^{80, 247}, Valgerdur Steinthorsdottir¹⁷, Heather
 894 Stringham¹¹², Michael Stumvoll^{52, 53}, Praveen Surendran⁶⁵, Leen M t Hart²⁴⁸⁻²⁵⁰, Katherine
 895 E Tansey^{251, 252}, Jean-Claude Tardif^{5, 238}, Kent D Taylor^{75, 253}, Alexander Teumer²⁵⁴,
 896 Deborah J Thompson⁹⁷, Unnur Thorsteinsdottir^{17, 128}, Betina H Thuesen¹⁶⁴, Anke Tönjes²⁵⁵,
 897 Gerard Tromp^{67, 256}, Stella Trompet^{166, 257}, Emmanouil Tsafantakis²⁵⁸, Jaakko
 898 Tuomilehto^{203, 259-261}, Anne Tybjaerg-Hansen^{50, 122}, Jonathan P Tyrer¹⁰², Rudolf Uher²⁶²,
 899 André G Uitterlinden, Sheila Ulivi^{3, 4}, Sander W van der Laan²²³, Andries R Van Der
 900 Leij²⁶³, Cornelia M van Duijn³, Natasja M van Schoor²⁶⁴, Jessica van Setten⁴², Anette
 901 Varbo^{49, 50}, Tibor V Varga¹¹⁹, Rohit Varma¹⁵⁹, Digna R Velez Edwards²⁶⁵, Sita H
 902 Vermeulen³¹, Henrik Vestergaard³⁵, Veronique Vitart¹³⁴, Thomas F Vogt²⁶⁶, Diego
 903 Vozzi¹²⁴, Mark Walker²⁶⁷, Feijie Wang¹⁹⁹, Carol A Wang²²⁴, Shuai Wang²⁶⁸, Yiqin
 904 Wang¹⁹⁹, Nicholas J Wareham¹⁹³, Helen R Warren^{1, 68}, Jennifer Wessel²⁶⁹, Sara M
 905 Willems¹⁹³, James G Wilson²⁷⁰, Daniel R Witte^{271, 272}, Michael O Woods²⁷³, Ying Wu¹⁹¹,
 906 Hanieh Yaghootkar²⁷⁴, Jie Yao⁷⁵, Pang Yao¹⁹⁹, Laura M Yerges-Armstrong^{218, 275}, Robin
 907 Young^{65, 117}, Eleftheria Zeggini⁸⁶, Xiaowei Zhan²⁷⁶, Weihua Zhang^{69, 70}, Jing Hua Zhao¹⁹³,
 908 Wei Zhao²⁴⁰, Wei Zhao⁵¹, He Zheng¹⁹⁹, Wei Zhou^{168, 169}, EPIC-CVD Consortium[¶], The
 909 EPIC-InterAct consortium[¶], CHD Exome+ Consortium[¶], MAGIC Consortium[¶], ExomeBP
 910 Consortium[¶], T2D-Genes Consortium[¶], GoT2D Genes Consortium[¶], Jerome I Rotter⁷⁵,
 911 Michael Boehnke¹¹², Sekar Kathiresan^{8, 74, 106}, Mark I McCarthy^{22, 175, 176}, Cristen J
 912 Willer^{168, 169, 277}, Kari Stefansson^{17, 128}, Ingrid B Borecki¹¹¹, Dajiang J Liu²⁷⁸, Kari E
 913 North²⁷⁹, Nancy L Heard-Costa^{77, 280}, Tune H Pers^{35, 281}, Cecilia M Lindgren^{22, 282}, Claus
 914 Oxvig^{7*}, Zoltán Kutalik^{15, 16*}, Fernando Rivadeneira^{3, 4*}, Ruth JF Loos^{12, 13, 283*}, Timothy
 915 M Frayling^{274*}, Joel N Hirschhorn^{8, 10, 284*}, Panos Deloukas^{1, 285*}, Guillaume Lettre^{5, 238*}
 916

917

918 *These authors contributed equally to this work.

919 †A full list of members and affiliations appears in the **Supplementary Note**

920 Correspondence should be addressed to JNH (joelh@broadinstitute.org), PD

921 (p.deloukas@qmul.ac.uk) or GL (guillaume.lettre@umontreal.ca).

922

923 Affiliations

924

925 1 William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary
926 University of London, London, EC1M 6BQ, UK

927 2 Department of Epidemiology, University of North Carolina, Chapel Hill, NC, 27514, USA

928 3 Department of Epidemiology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands

929 4 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands

930 5 Montreal Heart Institute, Université de Montréal, Quebec, H1T 1C8, Canada

931 6 Genetics of Complex Traits, Institute of Biomedical and Clinical Science, University of Exeter Medical School,
932 Exeter, EX2 5DW, UK

933 7 Department of Molecular Biology and Genetics, Aarhus University, Aarhus, 8000, Denmark

934 8 Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA

935 9 Department of Genetics, Harvard Medical School, Boston, MA, 02115, USA

936 10 Division of Endocrinology and Center for Basic and Translational Obesity Research, Boston Children's
937 Hospital, Boston, MA, 02115, USA

938 11 Division of Epidemiology, Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt

939 Epidemiology Center, Vanderbilt University School of Medicine, Nashville, TN, 37203, USA

940 12 The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New
941 York, NY, 10029, USA

942 13 The Genetics of Obesity and Related Metabolic Traits Program, Ichan School of Medicine at Mount Sinai, New
943 York, NY, 10069, USA

944 14 Human Genetics Center, The University of Texas School of Public Health, The University of Texas Graduate
945 School of Biomedical Sciences at Houston, The University of Texas Health Science Center at Houston,

946 Houston, TX, 77030, USA

947 15 Institute of Social and Preventive Medicine, Lausanne University Hospital, Lausanne, 1010, Switzerland

948 16 Swiss Institute of Bioinformatics, Lausanne, 1015, Switzerland

949 17 deCODE Genetics/Amgen inc., Reykjavik, 101, Iceland

950 18 Department of Computational Biology, University of Lausanne, Lausanne, 1011, Switzerland

951 19 Department of Haematology, University of Cambridge, Cambridge, CB2 0PT, UK

952 20 Department of Genetic Epidemiology, University of Regensburg, Regensburg, D-93051, Germany

953 21 Estonian Genome Center, University of Tartu, Tartu, 51010, Estonia

954 22 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, OX3 7BN, UK

955 23 Center for Statistical Genetics and Department of Biostatistics, University of Michigan, Ann Arbor, MI, 43109,
956 USA

957 24 McDonnell Genome Institute, Washington University School of Medicine, Saint Louis, MO, 63108, USA

958 25 Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, LE3 9QP, UK

959 26 NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, UK

960 27 Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA

961 28 Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem,
962 NC, 27157, USA

963 29 Nuffield Department of Clinical Medicine, Oxford, OX37BN, UK

964 30 Netherlands Comprehensive Cancer Organisation, Utrecht, 3501 DB, The Netherlands

965 31 Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, 6500 HB, The
966 Netherlands

967 32 Department of Nutrition, University of North Carolina, Chapel Hill, NC, 27599, USA

968 33 Centre for Control of Chronic Diseases (CCCCD), Dhaka, 1212, Bangladesh

969 34 Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental
970 Health, Neuherberg, D-85764, Germany

971 35 The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences,
972 University of Copenhagen, Copenhagen, 2100, Denmark

973 36 Department of Family Medicine & Public Health, University of California, San Diego, La Jolla, CA, 92093,
974 USA

975 37 INSERM U1167, Lille, F-59019, France

976	38	Institut Pasteur de Lille, U1167, Lille, F-59019, France
977	39	Universite de Lille, U1167 - RID-AGE - Risk factors and molecular determinants of aging-related diseases, Lille, F-59019, France
978		
979	40	Department of Epidemiology and Public Health, University of Strasbourg, Strasbourg, F-67085, France
980	41	Department of Public Health, University Hospital of Strasbourg, Strasbourg, 67081, France
981	42	Department of Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, The Netherlands
982		
983	43	Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The Netherlands
984	44	Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK
985		
986	45	Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI, 53201, USA
987	46	INSERM U1018, Centre de recherche en Épidémiologie et Sante des Populations (CESP), Villejuif, France
988	47	Department of Nephrology, University Hospital Regensburg, Regensburg, 93042, Germany
989	48	Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, 2100, Denmark
990	49	Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, 2730, Denmark
991		
992	50	Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, 2200, Denmark
993	51	Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, 48109, USA
994	52	IFB Adiposity Diseases, University of Leipzig, Leipzig, 04103, Germany
995	53	University of Leipzig, Department of Medicine, Leipzig, 04103, Germany
996	54	Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, 14558, Germany
997		
998	55	School of Public Health, Human Genetics Center, The University of Texas Health Science Center at Houston, Houston, TX, 77030, USA
999		
1000	56	Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030 USA
1001	57	Medical Genomics and Metabolic Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 20892, USA
1002		
1003	58	Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands
1004		
1005	59	Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
1006	60	Department of Clinical Biochemistry, Lillebaelt Hospital, Vejle, 7100, Denmark
1007	61	Institute of Regional Health Research, University of Southern Denmark, Odense, 5000, Denmark
1008	62	MRC Social Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King's College London & NIHR Biomedical Research Centre for Mental Health at the Maudsley, London, SE5 8AF, UK
1009		
1010		
1011	63	Marshfield Clinic Research Foundation, Marshfield, WI, 54449, USA
1012	64	Department of Medicine, University of Washington, Seattle, WA, 98195, USA
1013	65	Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK
1014		
1015	66	The National Institute for Health Research Blood and Transplant Unit (NIHR BTRU) in Donor Health and Genomics at the University of Cambridge, University of Cambridge, Cambridge, CB1 8RN, UK
1016		
1017	67	The Sigfried and Janet Weis Center for Research, Danville, PA, 17822, USA
1018	68	NIHR Barts Cardiovascular Research Unit, Barts and The London School of Medicine & Dentistry, Queen Mary University, London, EC1M 6BQ, UK
1019		
1020	69	Department of Cardiology, London North West Healthcare NHS Trust, Ealing Hospital, Middlesex, UB1 3HW, UK
1021		
1022	70	Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK
1023		
1024	71	Imperial College Healthcare NHS Trust, London, W12 0HS, UK
1025	72	Division of Genetics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
1026	73	Division of Preventive Medicine, Brigham and Women's and Harvard Medical School, Boston, MA, 02215, USA
1027		
1028	74	Harvard Medical School, Boston, MA, 02215, USA
1029	75	Institute for Translational Genomics and Population Sciences, LABioMed at Harbor-UCLA Medical Center, Torrance, CA, 90502, USA
1030		
1031	76	Medical department, Lillebaelt Hospital, Vejle, 7100, Denmark
1032	77	NHLBI Framingham Heart Study, Framingham, MA, 01702, USA
1033	78	Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, 34100, Italy
1034	79	Department of Biostatistics, University of Liverpool, Liverpool, L69 3GL, UK
1035	80	Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
1036	81	Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
1037	82	Department of Human Genetics, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands

1038	83	Molecular Basis of Disease, Griffith University, Southport, QLD, Australia
1039	84	Diamantina Institute, University of Queensland, Brisbane, Queensland, 4072, Australia
1040	85	QIMR Berghofer Medical Research Institute, Brisbane, Queensland, 4006, Australia
1041	86	Wellcome Trust Sanger Institute, Hinxton, CB10 1SA, UK
1042	87	Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, 3584 CG, The Netherlands
1043		
1044	88	Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands
1045		
1046	89	Department of Surgery, Division of Surgical Specialties, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands
1047		
1048	90	Faculty of Pharmacy, Université de Montréal, Montreal, Quebec, H3T 1J4, Canada
1049	91	Department of Clinical Chemistry and Haematology, Division of Laboratory and Pharmacy, University Medical Center Utrecht, Utrecht, 3508 GA, The Netherlands
1050		
1051	92	Utrecht Institute for Pharmaceutical Sciences, Division Pharmacoepidemiology & Clinical Pharmacology, Utrecht University, Utrecht, 3508 TB, The Netherlands
1052		
1053	93	Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, 2300RC, The Netherlands
1054	94	Department of Nutrition and Dietetics, School of Health Science and Education, Harokopio University, Athens, 17671, Greece
1055		
1056	95	Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, 55454, USA
1057		
1058	96	Department of Ophthalmology, Radboud University Medical Center, Nijmegen, 6500 HB, The Netherlands
1059	97	Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, CB1 8RN, UK
1060		
1061	98	Institute of Cardiovascular Science, University College London, London, WC1E 6JF, UK
1062	99	MRC Integrative Epidemiology Unit, School of Social & Community Medicine, University of Bristol, Bristol, BS8 2BN, UK
1063		
1064	100	Fred Hutchinson Cancer Research Center, Public Health Sciences Division, Seattle, WA, 98109, USA
1065	101	Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, New York, NY, 10017, USA
1066		
1067	102	Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, CB1 8RN, UK
1068		
1069	103	Department of Medicine, Oulu University Hospital, Oulu, 90029, Finland
1070	104	Research Unit of Internal Medicine, University of Oulu, Oulu, FI-90014, Finland
1071	105	Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN, 37203, USA
1072		
1073	106	Massachusetts General Hospital, Boston, MA, 02114, USA
1074	107	Medical and Population Genetics Program, Broad Institute, Cambridge, MA, 02141, USA
1075	108	Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, W2 1PG, UK
1076		
1077	109	Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, 45110, Greece
1078	110	Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor, MI, 48104, USA
1079	111	Division of Statistical Genomics, Department of Genetics, Washington University School of Medicine, St. Louis, MO, 63108, USA
1080		
1081	112	Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, 48109, USA
1082		
1083	113	CNR Institute of Clinical Physiology, Pisa, Italy
1084	114	Department of Clinical & Experimental Medicine, University of Pisa, Italy
1085	115	Research center on Epidemiology and Preventive Medicine, dept. Of clinical and experimental medicine, University of Insubria, Varese, 21100, Italy
1086		
1087	116	Toulouse University School of Medicine, Toulouse, TSA 50032 31059, France
1088	117	University of Glasgow, Glasgow, G12 8QQ, UK
1089	118	Institute of Molecular Medicine University of Texas Health Science Center at Houston, Houston, TX, 77030, USA
1090		
1091	119	Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, SE-20502, Sweden
1092		
1093	120	Department of Nutrition, Harvard School of Public Health, Boston, MA, 02115, USA
1094	121	Department of Public Health and Clinical Medicine, Unit of Medicine, Umeå University, Umeå, 901 87, Sweden
1095		
1096	122	Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen, 2100, Denmark
1097		
1098	123	Department of Medical Sciences, University of Trieste, Trieste, 34137, Italy
1099	124	Division of Experimental Genetics, Sidra Medical and Research Center, Doha, 26999, Qatar

1100	125	Geriatrics, Department of Public Health, Uppsala University, Uppsala, 751 85, Sweden
1101	126	Carolina Population Center, University of North Carolina, Chapel Hill, NC, 27514, USA
1102	127	Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, 27514, USA
1103		
1104	128	Faculty of Medicine, University of Iceland, Reykjavik, 101, Iceland
1105	129	Icelandic Heart Association, Kopavogur, 201, Iceland
1106	130	Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala University, Uppsala, 751 41, Sweden
1107		
1108	131	Department of Sociology, University of North Carolina, Chapel Hill, NC, 27514, USA
1109	132	Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, National Institutes of Health, Bethesda, MD, 20892, USA
1110		
1111	133	University of Exeter Medical School, University of Exeter, Exeter, EX2 5DW, UK
1112	134	MRCHGU, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
1113	135	Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC, 27708, USA
1114		
1115	136	Department of Public Health, University of Helsinki, Helsinki, FI-00014, Finland
1116	137	Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, FI-00014, Finland
1117	138	Department of Pediatrics, Haukeland University Hospital, Bergen, 5021, Norway
1118	139	KG Jebsen Center for Diabetes Research, Department of Clinical Science, University of Bergen, Bergen, 5020, Norway
1119		
1120	140	Department of Cardiology, Heart Hospital, Tampere University Hospital, Tampere, 33521, Finland
1121	141	Department of Clinical Chemistry, Fimlab Laboratories, Tampere, 33520, Finland
1122	142	Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere, 33014, Finland
1123	143	Centre for Eye Research Australia, Royal Victorian Eye and Ear Hospital, University of Melbourne, Melbourne, Victoria, 3002, Australia
1124		
1125	144	Centre for Ophthalmology and Vision Science, Lions Eye Institute, University of Western Australia, Perth, Western Australia, 6009, Australia
1126		
1127	145	Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, 7000, Australia
1128	146	Generation Scotland, Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
1129		
1130	147	Musculoskeletal Research Programme, Division of Applied Medicine, University of Aberdeen, Aberdeen, AB25, UK
1131		
1132	148	K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health, NTNU, Norwegian University of Science and Technology, Trondheim, 7600, Norway
1133		
1134	149	AMC, Department of Vascular Medicine, Amsterdam, 1105 AZ, The Netherlands
1135	150	HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, 7600, Norway
1136		
1137	151	Department of Neurology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands
1138	152	Department of Radiology, Erasmus Medical Center, Rotterdam, 3015 GE, The Netherlands
1139	153	Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, 943 05, USA
1140		
1141	154	Department of Public Health & Clinical Medicine, Umeå University, Umeå, SE-90185, Sweden
1142	155	Research Unit Skellefteå, Skellefteå, SE-93141, Sweden
1143	156	Department of Genome Sciences, University of Washington, Seattle, WA, 98195, USA
1144	157	The Copenhagen City Heart Study, Frederiksberg Hospital, Frederiksberg, 2000, Denmark
1145	158	Department of Preventive Medicine, Keck School of Medicine of the University of California, Los Angeles, California, USA, 90089, USA
1146		
1147	159	USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, 90089, USA
1148		
1149	160	Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, 5021, Norway
1150	161	National Institute of Public Health, University of Southern Denmark, Copenhagen, 1353, Denmark
1151	162	Steno Diabetes Center, Gentofte, 2820, Denmark
1152	163	Aalborg University, Aalborg, DK-9000, Denmark
1153	164	Research Center for Prevention and Health, Capital Region of Denmark, Glostrup, DK-2600, Denmark
1154	165	Department of Health, National Institute for Health and Welfare, Helsinki, 00271, Finland
1155	166	Department of Cardiology, Leiden University Medical Center, Leiden, 2333, The Netherlands
1156	167	The Interuniversity Cardiology Institute of the Netherlands, Utrecht, 2333, The Netherlands
1157	168	Department of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48109, USA
1158		
1159	169	Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 48109, USA
1160	170	Division of Gastroenterology, University of Michigan, Ann Arbor, MI, 48109, USA
1161	171	Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, 3584 CG,

1162		The Netherlands
1163	172	Department of Clinical Physiology, University of Tampere School of Medicine, Tampere, 33014, Finland
1164	173	National Institute for Health and Welfare, Helsinki, FI-00271, Finland
1165	174	Echinos Medical Centre, Echinos, Greece
1166	175	Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, Oxford, OX3 7LE, UK
1167		
1168	176	Oxford NIHR Biomedical Research Centre, Oxford University Hospitals Trust, Oxford, OX3 7LE, UK
1169	177	UKCRC Centre of Excellence for Public Health Research, Queens University Belfast, Belfast, UK, BT12 6BJ,
1170		UK
1171	178	Netherlands Cancer Institute - Antoni van Leeuwenhoek hospital, Amsterdam, 1066 CX, The Netherlands
1172	179	Department of Restorative Dentistry, Periodontology and Endodontology, University Medicine Greifswald, Greifswald, 17475, Germany
1173		
1174	180	Foundation for Research in Health Exercise and Nutrition, Kuopio Research Institute of Exercise Medicine, Kuopio, 70100, Finland
1175		
1176	181	National Heart and Lung Institute, Imperial College London, Hammersmith Hospital Campus, London, W12 0NN, UK
1177		
1178	182	Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle WA, 98109, USA
1179	183	German Center for Diabetes Research, Neuherberg, D-85764, Germany
1180	184	Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, D-85764, Germany
1181		
1182	185	Research Unit of Molecular Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, D-85764, Germany
1183		
1184	186	Department of Psychiatry, and Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, Western Cape, 7505, South Africa
1185		
1186		
1187	187	CHU Nantes, Service de Génétique Médicale, Nantes, 44093, France
1188	188	Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, 70210, Finland
1189		
1190	189	Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, 34137, Italy
1191	190	Institute of Biomedicine & Physiology, University of Eastern Finland, Kuopio, 70210, Finland
1192	191	Department of Genetics, University of North Carolina, Chapel Hill, NC, 27514, USA
1193	192	Department of Biostatistical Sciences and Center for Public Health Genomics, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
1194		
1195	193	MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge, CB2 0QQ, UK
1196		
1197	194	Group Health Research Institute, Seattle, WA, 98101, USA
1198	195	Department of Health Services, University of Washington, Seattle WA 98101
1199	196	Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan 407, Taiwan
1200		
1201	197	School of Medicine, National Yang-Ming School of Medicine, Chung Shan Medical University, Taipei, Taiwan 112, Taiwan
1202		
1203	198	Division of Preventive Medicine University of Alabama at Birmingham, Birmingham, AL, AL 35205, USA
1204	199	Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai, People's Republic of China, Shanghai, 200031, China
1205		
1206		
1207	200	Department of Medicine, Division of Cardiovascular Medicine, Stanford University School of Medicine, Palo Alto, CA, 94304, USA
1208		
1209	201	Department of Medicine, Boston University School of Medicine, Boston, MA, 02118, USA
1210	202	Uppsala University, Uppsala, 75185, Sweden
1211	203	Chronic Disease Prevention Unit, National Institute for Health and Welfare, Helsinki, 00271, Finland
1212	204	Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 27157, USA
1213	205	Division of Health Sciences, Warwick Medical School, Warwick University, Coventry, CV4 7AL, UK
1214	206	Department of Psychiatry, Washington University, Saint Louis, MO, 63110, USA
1215	207	Department of Medicine, Harvard University Medical School, Boston, MA, 02115, USA
1216	208	Department of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke (DIfE), Nuthetal, 14558, Germany
1217		
1218	209	Westmead Millennium Institute of Medical Research, Centre for Vision Research and Department of Ophthalmology, University of Sydney, Sydney, New South Wales, 2022, Australia
1219		
1220	210	Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, 2300RC, The Netherlands
1221		
1222	211	Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, EH8 9AG, UK
1223		

1224	212	Department of Medicine I, Ludwig-Maximilians-Universität, Munich, 81377, Germany
1225	213	DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, 80802, Germany
1226		
1227	214	Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD, 20892, USA
1228	215	DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald, 17475, Germany
1229	216	Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, 17475, Germany
1230		
1231	217	Department of Cardiology, Heart Center, Tampere University Hospital and School of Medicine, University of Tampere, Tampere, 33521, Finland
1232		
1233	218	Program in Personalized Medicine, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, 21201, US
1234		
1235	219	Department of Medicine, Tampere University Hospital, Tampere, 33521, Finland
1236	220	Center for Neurobehavioral Genetics, UCLA, Los Angeles, CA, 90095, USA
1237	221	Pat Macpherson Centre for Pharmacogenetics and Pharmacogenomics, Medical Research Institute, Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK
1238		
1239	222	Laboratory of Clinical Chemistry and Hematology, Division Laboratories and Pharmacy, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands
1240		
1241	223	Laboratory of Experimental Cardiology, Division Heart & Lungs, University Medical Center Utrecht, Utrecht, 3584 CX, The Netherlands
1242		
1243	224	School of Womenis and Infants Health, The University of Western Australia, Perth, Western Australia, 6009, Australia
1244		
1245	225	University of Helsinki, Institute for Molecular Medicine (FIMM) and Diabetes and Obesity Research Program, Helsinki, FI00014, Finland
1246		
1247	226	University of Tartu, Estonian Genome Center, Tartu, Estonia, Tartu, 51010, Estonia
1248	227	School of Medicine, University of Split, Split, 21000, Croatia
1249	228	Center for Neurogenetics and Cognitive Research, Department Complex Trait Genetics, VU University, Amsterdam, 1081 HV, The Netherlands
1250		
1251	229	Neuroscience Campus Amsterdam, Department Clinical Genetics, VU Medical Center, Amsterdam, 1081 HV, The Netherlands
1252		
1253	230	Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku, 20521, Finland
1254	231	Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, 20520, Finland
1255		
1256	232	Centre for Non-Communicable Diseases, Karachi, Pakistan
1257	233	Kuopio University Hospital, Department of Clinical Physiology and Nuclear Medicine, Kuopio, 70210, Finland
1258	234	Merck Research Laboratories, Genetics and Pharmacogenomics, Boston, MA, 02115, USA
1259	235	Department of Epidemiology, University of Washington, Seattle, WA, 98195, USA
1260	236	Department of Biobank Research, Umeå University, Umeå, SE-90187, Sweden
1261	237	Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, USA
1262		
1263	238	Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, H3T 1J4, Canada
1264	239	Department of Public Health and Clinical Medicine, Unit of Family Medicine, Umeå University, Umeå, 90185, Sweden
1265		
1266	240	Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
1267		
1268	241	Division of Epidemiology & Community Health University of Minnesota, Minneapolis, MN, 55454, USA
1269	242	Duke University, Durham, NC, 27703, USA
1270	243	Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore, Singapore
1271		
1272	244	Department of Haematology, University of Cambridge, Cambridge, CB2 0PT, UK
1273	245	Department of Vascular Medicine, AMC, Amsterdam, 1105 AZ, The Netherlands
1274	246	Department of Twin Research and Genetic Epidemiology, King's College London, London, SE1 7EH, UK
1275	247	Alzheimer Scotland Dementia Research Centre, University of Edinburgh, Edinburgh, EH8 9JZ, UK
1276	248	Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, 1081BT, The Netherlands
1277		
1278	249	Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, 2333ZC, The Netherlands
1279	250	Department of Molecular Epidemiology, Leiden University Medical Center, Leiden, 2333ZC, The Netherlands
1280	251	College of Biomedical and Life Sciences, Cardiff University, Cardiff, CF14 4EP, UK
1281	252	MRC Integrative Epidemiology Unit, School of Social and Community Medicine, University of Bristol, Bristol, BS8 2BN, UK
1282		
1283	253	Los Angeles Biomedical Research Institute at Harbor, UCLA, Los Angeles, CA, 90095, USA
1284	254	Institute for Community Medicine, University Medicine Greifswald, Greifswald, 17475, Germany
1285	255	Center for Pediatric Research, Department for Womenis and Child Health, University of Leipzig, Leipzig,

1286 04103, Germany
 1287 256 Division of Molecular Biology and Human Genetics, Department of Biomedical Sciences, Faculty of Medicine
 1288 and Health Sciences, Stellenbosch University, Tygerberg, Western Cape, 7505, South Africa
 1289 257 Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, 2333, The Netherlands
 1290 258 Anogia Medical Centre, Anogia, Greece
 1291 259 Centre for Vascular Prevention, Danube-University Krems, Krems, 3500, Austria
 1292 260 Dasman Diabetes Institute, Dasman, 15462, Kuwait
 1293 261 Diabetes Research Group, King Abdulaziz University, Jeddah, 21589, Saudi Arabia
 1294 262 Department of Psychiatry, Dalhousie University, Halifax, B3H 4R2, Canada
 1295 263 University of Amsterdam, Department of Brain & Cognition, Amsterdam, 1018 WS, The Netherlands
 1296 264 VU University Medical Center, Department of Epidemiology and Biostatistics, Amsterdam, 1007 MB, The
 1297 Netherlands
 1298 265 Department of Obstetrics and Gynecology, Institute for Medicine and Public Health, Vanderbilt Genetics
 1299 Institute, Vanderbilt University, Nashville, TN, 37203, USA
 1300 266 Merck Research Laboratories, Cardiometabolic Disease, Kenilworth, NJ, 07033, USA
 1301 267 Institute of Cellular Medicine, The Medical School, Newcastle University, Newcastle, NE2 4HH, UK
 1302 268 Department of Biostatistics, Boston University School of Public Health, Boston, MA, 02118, USA
 1303 269 Departments of Epidemiology & Medicine, Diabetes Translational Research Center, Fairbanks School of Public
 1304 Health & School of Medicine, Indiana University, Indiana, IN, 46202, USA
 1305 270 Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, 39216,
 1306 USA
 1307 271 Danish Diabetes Academy, Odense, 5000, Denmark
 1308 272 Department of Public Health, Aarhus University, Aarhus, 8000, Denmark
 1309 273 Memorial University, Faculty of Medicine, Discipline of Genetics, St. John's, NL, A1B 3V6, Canada
 1310 274 Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, EX2 5DW, UK
 1311 275 GlaxoSmithKlein, King of Prussia, PA, 19406, USA
 1312 276 Department of Clinical Sciences, Quantitative Biomedical Research Center, Center for the Genetics of Host
 1313 Defense, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA
 1314 277 Department of Human Genetics, University of Michigan, Ann Arbor, MI, 48109, USA
 1315 278 Department of Public Health Sciences, Institute for Personalized Medicine, the Pennsylvania State University
 1316 College of Medicine, Hershey, PA, 17033, USA
 1317 279 Department of Epidemiology and Carolina Center of Genome Sciences, Chapel Hill, NC, 27514, USA
 1318 280 Department of Neurology, Boston University School of Medicine, Boston, MA, 02118, USA
 1319 281 Department of Epidemiology Research, Statens Serum Institut, Copenhagen, 2200, Denmark
 1320 282 Li Ka Shing Centre for Health Information and Discovery, The Big Data Institute, University of Oxford,
 1321 Oxford, OX3 7BN, UK
 1322 283 The Mindich Child Health and Development Institute, Ichan School of Medicine at Mount Sinai, New York,
 1323 NY, 10069, USA
 1324 284 Departments of Pediatrics and Genetics, Harvard Medical School, Boston, MA, 02115, USA
 1325 285 Princess Al-Jawhara Al-Brahim Centre of Excellence in Research of Hereditary Disorders (PACER-HD), King
 1326 Abdulaziz University, Jeddah, 21589, Saudi Arabia
 1327
 1328